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ABSTRACT 
______________________________________________________________________________ 
 
Background: Insulin resistance (IR) can contribute to the development of type 2 diabetes. 
Asymptomatic individuals with high insulin resistance benefit from early interventions to 
prevent the progression to overt diabetes. Multiple causes of IR have been identified, many of 
which are reversible. It has been suggested that inflammation may contribute to IR. Our study 
aims to determine the association between insulin resistance and the inflammatory marker C - 
reactive protein (CRP) in the non-diabetic Canadian population and, furthermore, to examine 
potential differences in this association by gender, age, and at different serum levels of glucose 
and HbA1c.  
Methods: We examined 2963 non-diabetic adults who participated in the Canadian Health 
Measures Survey, which is a national cross-sectional survey of the general Canadian population. 
Insulin resistance was calculated by HOMAIR. Individuals with an acute or chronic condition or 
those who were taking a platelet aggregation inhibitor or HMG-CoA reductase inhibitor were 
excluded because it can interfere with CRP levels.  A cut off level of 3mg/L was used to define 
high and low CRP. Multiple linear regression was performed for statistical analysis.   
Results: After adjusting for age, race, sex, smoking history, blood pressure, triglyceride, LDL, 
HDL, BMI, waist circumference and hip circumference, the insulin resistance, as reported by 
HOMAIR, was greater with high levels of CRP. HOMAIR for low and high CRP were 1.59 
(95% CI: 1.51-1.61) and 2.76 (2.41-3.11) respectively in age group 18-30, 1.60 (1.55-1.65) and 
2.58 (2.42-3.2.75) in age group 31-45 years, 1.68 (1.62-1.74) and 2.66 (2.47-2.86) in age group 
46-60 years, and 1.82 (1.74-1.90) and 2.44 (2.26-2.62) in age group 61 and older. The results 
were statistically significant (P<0.01). Insulin resistance was also elevated with high CRP in both 
men and women. HOMAIR in men was 1.81 (1.77-1.86) and 2.88 (2.72-3.06) with low and high 
CRP respectively (p<0.05). Whereas in women it was 1.48 (1.44-1.51) and 2.43 (2.29-2.57) with 
low and high CRP respectively (p<0.05). Adjusted HOMAIR was also positively associated with 
CRP independent of the level of fasting glucose and HbA1c level. 
Conclusion: Our study demonstrated a significant and positive association between insulin 
resistance and inflammatory markers in the Canadian population. Future studies are needed to 
confirm our findings and determine role of anti-inflammatory drugs in the prevention of diabetes.  
iii 
 
 
ACKNOWLEDGMENT 
_____________________________________________________________________________ 
 
This work would not have been possible without the support and help of many individuals 
including my supervisor, the thesis committee members, my family, and my colleagues. 
 
I would like to express my indebtedness and deepest gratitude to my thesis supervisor Dr. Punam 
Pahwa for her keen interest, valuable guidance, and endless support at the various stages of this 
work. She is a great mentor and her guidance helped me complete this work. I would like to 
extend my deepest appreciation and gratitude to the committee members, including Dr. Bonnie 
Janzen, the committee chairperson, and Dr. Terra Arnason, from the Department of Medicine at 
the University of Saskatchewan. A special thanks to my husband Shahid, and children Rafay and 
Anaya, for all the sacrifices that you have made on my behalf.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
iv 
 
TABLE OF CONTENTS 
______________________________________________________________________________ 
 
PERMISSION TO USE ................................................................................................................... i	
DISCLAIMER ................................................................................................................................. i	
ABSTRACT .................................................................................................................................... ii	
ACKNOWLEDGMENT ................................................................................................................ iii	
TABLE OF CONTENTS ............................................................................................................... iv	
LIST OF TABLES ........................................................................................................................ vii	
LIST OF FIGURES ...................................................................................................................... vii	
LIST OF ABBREVIATIONS ...................................................................................................... viii	
CHAPTER ONE:  INTRODUCTION ............................................................................................ 1	
1.1 Rationale of the Study ........................................................................................................... 1	
1.2 Research Questions ............................................................................................................... 2	
1.3 Primary Objective ................................................................................................................. 2	
1.4 Secondary Objectives ............................................................................................................ 2	
CHAPTER TWO:  DIABETES AND INSULIN RESISTANCE .................................................. 4	
2.1 Definition and Type of Diabetes ........................................................................................... 4	
2.2 Natural History of Type 2 Diabetes ...................................................................................... 4	
2.3 Prediabetes ............................................................................................................................ 5	
2.4 Pathogenesis of Insulin Resistance ....................................................................................... 7	
2.5 Etiology of Insulin Resistance .............................................................................................. 8	
2.6 Methods to Measure Insulin Resistance ............................................................................... 9	
2.7 Thresholds for HOMAIR .................................................................................................... 10	
2.8.1	 Summary of Population Based Studies Defining the Threshold of HOMAIR ....... 11	
CHAPTER THREE: INFLAMMATION AND INSULIN RESISTANCE ................................. 16	
3.1 Inflammation and Inflammatory Markers ........................................................................... 16	
3.2 Inflammation and Diabetes ................................................................................................. 17	
3.2.2	 Previous Studies with Insulin Resistance and Inflammation in Selected 
Communities ......................................................................................................................... 20	
CHAPTER FOUR: STUDY METHODOLOGY ......................................................................... 25	
4.1 Canadian Health Measure Survey (CHMS) ............................................................................ 25	
4.1.1	 Household Component ............................................................................................ 26	
4.1.2	 Mobile Examination Center (MEC) ........................................................................ 26	
4.1.3	 Laboratory Component ........................................................................................... 27	
v 
 
4.1.4	 Biobank Component ............................................................................................... 27	
4.1.5	 Sampling Methodology ........................................................................................... 27	
4.1.6	 Estimation and Quality Control .............................................................................. 27	
4.1.7	 Fasted Sub-Sample .................................................................................................. 28	
4.1.8	 Cycle 1 (C1) (March 2007 to March 2009) ............................................................ 29	
4.1.9	 Cycle 2 (C2) (August 2009 to November 2011) ..................................................... 29	
4.1.10	 Cycle (C3) (January 2012 to December 2013) ....................................................... 30	
4.4 Inclusion Criteria ................................................................................................................ 30	
4.5 Exclusion Criteria ............................................................................................................... 30	
4.6 Dependent Variable ............................................................................................................ 31	
4.7 Independent Variables ........................................................................................................ 31	
4.8 Methods............................................................................................................................... 33	
4.9 Statistical Analysis .............................................................................................................. 33	
CHAPTER FIVE: RESULTS ....................................................................................................... 35	
5.1	 Population Characteristics .............................................................................................. 35	
5.2 Mean of Independent Variable in the Total Population by Sex .......................................... 37	
5.3 Mean of Independent Variable in the Total Population by Race ........................................ 39	
5.4 Observed HOMAIR ............................................................................................................ 42	
5.5 Association between Adjusted HOMAIR and CRP by Age from a Multivariable Model: 43	
5.6 Adjusted HOMAIR with CRP by Sex ................................................................................ 44	
5.7 Adjusted HOMAIR with CRP by Ethnicity ....................................................................... 47	
5.8 Adjusted HOMAIR with CRP by Various Levels of Glucose and HbA1c ........................ 47	
5.9 Confounding Factors to Consider ....................................................................................... 48	
5.10 Accounting for Possible Interactions ................................................................................ 49	
5.11 Sub-Group Analysis .......................................................................................................... 50	
CHAPTER SIX: DISCUSSION ................................................................................................... 52	
6.1	Insulin Resistance and Age ................................................................................................. 52	
6.2 Insulin Resistance and Sex .................................................................................................. 53	
6.3 Insulin Resistance and Ethnicity ......................................................................................... 54	
6.4 Insulin Resistance at Various Levels of Glycaemia ........................................................... 55	
6.5 Limitations and Strengths of the Study ............................................................................... 56	
CHAPTER SEVEN: SUMMARY AND FUTURE DIRECTIONS ............................................. 58	
7.1 Summary ............................................................................................................................. 58	
7.2 Future Directions ................................................................................................................ 58	
vi 
 
REFERENCES ............................................................................................................................. 59	
APPENDIX A ............................................................................................................................... 73	
APPENDIX B ............................................................................................................................... 74	
APPENDIX C ............................................................................................................................... 75	
APPENDIX D ............................................................................................................................... 76	
APPENDIX E ............................................................................................................................... 77	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
vii 
 
LIST OF TABLES                                                                            
______________________________________________________________________________ 
 
TABLE 2.8.1 SUMMARY OF POPULATION BASED STUDIES DEFINING THE 
THRESHOLD OF HOMAIR ............................................................................................... 11 
TABLE 5.1 POPULATION CHARACTERISTICS .................................................................... 36 
TABLE 5. 2: MEAN AND STANDARD DEVIATION OF INDEPENDENT VARIABLES IN 
MALE AND FEMALE ......................................................................................................... 38 
TABLE 5. 3: MEAN AND STANDARD DEVIATION OF INDEPENDENT VARIABLES BY 
RACE .................................................................................................................................... 40 
TABLE 5. 4: MEAN AND STANDARD DEVIATION OF INDEPENDENT VARIABLES BY 
VARIOUS LEVELS OF GLUCOSE AND HBA1C ........................................................... 41 
TABLE 5. 5: PERCENTILE OF OBSERVED HOMA-IR IN MALE AND FEMALE .............. 42 
TABLE 5. 6:  ADJUSTED HOMAIR WITH HIGH AND LOW CRP BY AGE (ADJUSTED 
FOR AGE, SEX, RACE, SMOKING, BLOOD PRESSURE, SYSTOLIC AND 
DIASTOLIC BLOOD PRESSURE, BMI, WAIST CIRCUMFERENCE, HDL, LDL, 
SERUM TOTAL CHOLESTEROL) .................................................................................... 43 
TABLE 5. 7: DIFFERENCE IN INSULIN RESISTANCE WITH HIGH AND LOW CRP IN 
MALE AND FEMALE ......................................................................................................... 46 
TABLE 5. 8: DIFFERENCE IN INSULIN RESISTANCE WITH HIGH AND LOW CRP BY 
AGE ...................................................................................................................................... 46 
TABLE 5. 9: DIFFERENCE IN INSULIN RESISTANCE WITH HIGH AND LOW CRP BY 
ETHNICITY ......................................................................................................................... 47 
TABLE 5. 10 DIFFERENCE IN INSULIN RESISTANCE WITH HIGH AND LOW CRP BY 
VARIUOUS LEVEL OF GLUCOSE AND HBA1C: (ADJUSTED FOR BMI AND WC) 48 
TABLE 5. 11 DIFFERENCE IN INUSLIN RESISTANCE WITH HIGH AND LOW CRP BY 
PHYSICAL ACTIVITY INDEX .......................................................................................... 51 
 
LIST OF FIGURES 
______________________________________________________________________________ 
 
FIGURE 5. 1 ERROR BAR PLOT: ASSOCIATION BETWEEN CRP AND HOMAIR BY 
AGE ...................................................................................................................................... 44 
FIGURE 5. 2 ERROR- BAR PLOT: ASSOCIATION BETWEEN CRP AND HOMAIR BY 
SEX ....................................................................................................................................... 45 
 
 
 
 
 
 
 
 
 
 
viii 
 
 
LIST OF ABBREVIATIONS 
______________________________________________________________________________ 
 
ADA – American Diabetic Association  
ANOVA – Analysis of variance 
BRAMS – Brazilian Metabolic Syndrome Study 
BMI – Body Mass Index 
CAPI – Computer-Assisted Personal Interviewing 
CDA – Canadian Diabetes Association 
CHMS – Canadian Health Measurement Survey 
CRP – C-Reactive Protein 
CV – Coefficient of Variation 
CVD – Cardiovascular Disease 
DECODA – Diabetes Epidemiology: Collaborative analysis Of Diagnostic Criteria in Asia 
DECODE – Diabetes Epidemiology: Collaborative analysis Of Diagnostic Criteria in Europe 
EGIR – European Group for the study of Insulin Resistance 
EPRICE – Epidemiological Study of Renal Insufficiency in Spain 
DM2 – Type 2 Diabetes  
FPG – Fasting Plasma Glucose 
HOMA – Homeostatic Model Assessment 
HDL – High-density lipoproteins  
hs-CRP – High Sensitive C-Reactive Protein 
IFG – Impaired Fasting Glucose 
IGT – Impaired Glucose Tolerance  
IL – Interleukin  
IR – Insulin Resistance 
IRAS – Insulin Resistance Atherosclerosis Study 
IRS – Insulin Resistance Syndrome 
LFS – Labor Force Survey 
MEC – Mobile Examination Center 
METSIM – Metabolic Syndrome in Men  
NAHANES – National Health and Nutrition Examination Survey 
NDDG – National Diabetes Data Groups 
NSAID – Non-steroidal anti-inflammatory drugs 
OGTT – Oral Glucose Tolerance Test  
OHS – Ontario Health Survey 
PAI-1 – Plasminogen activator inhibitor-1 
PIVUS – Prospective Investigation of the Vasculature in Uppsala Seniors 
TNF – Tumor Necrosis Factor 
TZD – Thiazolidinedione 
WHO – World Health Organization 
WOSCOPS - West of Scotland Coronary Prevention Study
1 
 
CHAPTER ONE:  INTRODUCTION 
______________________________________________________________________________ 
 
1.1 Rationale of the Study 
 
Diabetes mellitus type 2 (DM2) is a metabolic syndrome manifested by the presence of high 
blood sugars due to insufficient action of insulin and/or defects in insulin secretion1. The global 
prevalence of diabetes (type 1 and 2) among adults over eighteen years of age was 4.7% in 1980 
and it increased to 8.5% in 2014. As of 2016, 11 million Canadians have been diagnosed with 
diabetes or prediabetes, and this number is expected to increase to 13.9 million by 20262,3. 
Moreover, the prevalence of diabetes is projected to rise to approximately 11.6% (4.9 million) 
from 9.2% (3.5 million) over this same period2,3. The complications associated with diabetes can 
cause premature death and are associated with significant comorbidities. Diabetes is responsible 
for 30% of strokes, 40% of heart attacks, 50% of kidney failures requiring dialysis, and 70% of 
non-traumatic lower limb amputations3. People with diabetes are twenty-five times more likely 
to become blind than those without diabetes 4. Additionally, 15%–25% of people may develop 
serious foot infections associated with diabetes in their lifetime5. Between 2011 and 2012 one-
third of the amputations in Canada were performed due to diabetic foot infections6. In 2016, the 
cost of diabetes in Canada was $3.4 billion, and this cost was estimated to increase to $5 billion 
by 20262.  
 
Diabetes mellitus type 2 is the triad of insulin resistance, pancreatic beta cell dysfunction, and 
dysregulated hepatic glucose/glucagon production. IR is the main defect in DM27. An initial 
change in the pathogenesis of DM2 is the development of IR8,9. Insulin resistance, even before 
the development of diabetes, is known to increase the risk of cardiovascular diseases (CVD)10. 
Patients at this phase may benefit from lifestyle modification and pharmacological intervention 
to reverse insulin resistance and prevent the progression of a disease11.  
 
Multiple causes of insulin resistance have been identified, many of which are reversible. 
Correction of IR can preclude overt hyperglycemia and DM2. Chronic low-grade inflammation 
is emerging as a new risk factor for the development of diabetes12 with the assumption that 
correction of inflammation can help to offset insulin resistance. In low-grade inflammation, 
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classic clinical signs of inflammation are absent and only minor degrees of elevation in 
inflammatory markers are present when tested. This is different from acute inflammation and can 
occur in various chronic conditions and metabolic conditions such as coronary artery diseases, 
hypertension, and high cholesterol13, 14. Epidemiological studies show that minor degrees of 
elevation of multiple serum inflammatory markers are present in a high proportion of the general 
population and are associated with various lifestyle choices and common medical conditions 
such as atherosclerosis, osteoarthritis, and periodontis15,16. 
 
Correlation between inflammatory markers and insulin resistance have been explored in 
populations from Europe, Peru and USA17-20. Yet, data on the association of IR and 
inflammatory markers is relatively unexplored in the general Canadian population. To our 
knowledge, no population-based epidemiological study has been done that considers the 
association between insulin resistance and inflammatory markers in the Canadian population.  
 
1.2 Research Questions 
 
1. Is insulin resistance higher in the presence of low grade inflammation in the non-diabetic 
population? 
2. Does the relationship between insulin resistance and inflammation vary by age, gender, 
and ethnicity? 
 
1.3 Primary Objective 
 
1. The objective of this thesis is to examine the cross-sectional association between insulin 
resistance (HOMAIR) and the inflammatory marker CRP, in a representative sample of 
the Canadian non-diabetic population. 
 
1.4 Secondary Objectives  
 
Through a study of a representative sample of the Canadian non-diabetic population, we will: 
 
1. Compare the association of IR and CRP levels between men and women.  
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2. Examine the association between IR and CRP among different self-reported ethnic 
groups.  
3. Examine the difference in IR and CRP at various glucose and HbA1c level in non-
diabetic populations. 
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CHAPTER TWO:  DIABETES AND INSULIN RESISTANCE  
______________________________________________________________________________ 
 
2.1 Definition and Type of Diabetes 
 
Diabetes mellitus (type 1 and 2) is a metabolic disorder characterized by the presence of 
hyperglycemia due to defective insulin secretion, inadequate insulin action, or both21. The 
diagnostic criteria for diabetes promoted by Diabetes Canada is a fasting plasma glucose level of 
≥7.0 mmol/L, a 2-hour plasma glucose value after a 75-g oral glucose load of ≥11.1 mmol/L, or 
a glycated hemoglobin (HbA1c) value of ≥6.5%49. Type 1 diabetes is characterized by the 
destruction of pancreatic beta cells leading to absolute insulin deficiency. This is usually due to 
the autoimmune destruction of pancreatic beta cells21. The definite cause of type 1 diabetes is not 
known, and the disease is currently not preventable even in those with known autoantibodies22. 
DM2 is more common than type 1 as it accounts for more than 80% of all cases. Type 2 is the 
combination of genetic susceptibility, environmental influence, sedentary lifestyle, obesity, and 
acquired insulin resistance. Gestational diabetes mellitus refers to hyperglycemia with onset, or 
first recognition, during pregnancy. Other types of diabetes/hyperglycemia include a wide 
variety of relatively uncommon conditions, primarily specific genetically defined forms of 
diabetes or diabetes associated with other diseases or drug use22.  
 
2.2 Natural History of Type 2 Diabetes 
 
Diabetes mellitus type 2 accounts for 90-95% of diagnosed cases of diabetes, is caused by insulin 
resistance, and causes pancreatic beta cell dysfunction22. IR is the main defect in people with 
DM223. As the sensitivity to insulin by the body decreases, there is an increase in the amount of 
insulin that is released by the pancreatic cells to compensate. At the early stages, this 
compensation is successful. The compensation by pancreatic cells can keep glucose levels 
normal for several years, but its effect diminishes due to failing beta cell capacity. Clinically, this 
failure can be detected through impaired glucose tolerance with mild post-prandial blood glucose 
elevations and, as IR becomes worse, the pancreatic beta cell function declines resulting in 
impaired regulation of hepatic glucose production. Together, these defects lead to an increase in 
blood glucose. Beta cell dysfunction and IR can cause hyperglycemia which, in turn, can lead to 
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overt DM2. It can progress from an asymptomatic stage in the beginning with normal blood 
glucose to high blood glucose needing pharmacological intervention. 
 
A study of the natural history of diabetes is a key element in knowing the pathological 
differences between the early (insulin resistance) and late (insulinopenic) stages of the disease’s 
development. Understanding the stages of diabetes is an important factor in choosing treatment 
targets and modifying treatment approaches. The progression of diabetes from the asymptomatic 
stage to overt diabetes can take years or even decades.  Various lifestyle interventions, such as 
maintaining healthy body weight, can be effective in combating the progression of type 2 
diabetes. Current thought includes the possibility that pharmacological interventions aimed at 
reversing chronic low grade inflammation may also be a viable treatment target.  
 
 
2.3 Prediabetes 
 
Prediabetes refers to cases where testing indicates high glucose levels that still fall within the 
normal range, such as identification through the standard 75-gram oral glucose tolerance test. 
Impaired glucose tolerance and prediabetes are terms that were first introduced by the World 
Health Organization (WHO) and the National Diabetes Data Groups (NDDG) to replace the 
terms borderline, chemical, and asymptomatic diabetes. Later, different definitions of impaired 
glucose tolerance (IGT) have been recommended by various organizations and committees. The 
diagnostic criteria of prediabetes, fasting glucose levels, and average glucose levels have 
changed over time and include several complementary measures such as serum glucose levels 
and HbA1c levels. There is no worldwide agreement on the definition of impaired fasting 
glucose (IFG) and prediabetes. Diabetes Canada and the World Health Organization define 
impaired fasting glucose as a fasting plasma glucose (FPG) value of 6.1 to 6.9 mmol/L while the 
American Diabetic Association (ADA) defines it as a value of 5.6 to 6.9 mmol/L24,25. The 
American Diabetes Association defines prediabetes as an HbA1c between 5.7% and 6.4%, and 
Diabetes Canada includes an HbA1c between 6.0-6.4% as one of the diagnostic criteria for 
prediabetes24,25. However, HbA1c levels below 6.0% have been associated with an increased risk 
for diabetes26 and may be relevant to consider. In a systemic review of 44,203 individuals from 
sixteen cohort studies with a follow-up of 5.6 years, those with HbA1c between 5.5-6.0% had an 
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increased risk of diabetes (five-year incidence from 9-25%), and this is reflected in the ADA 
cutoff values of 5.7% and higher. Those with an HbA1c range of 6.0-6.5% had a five-year risk of 
developing diabetes between 25-50%. The combination of an FPG of 6.1 to 6.9 mmol/L and an 
HbA1c of 6.0% to 6.4% is predictive of 100% progression to type 2 diabetes over a five-year 
period, without intervention27. 
 
Not all individuals with prediabetes will progress to diabetes. It has been shown in large clinical 
cohorts that approximately one-third of the individuals with impaired glucose tolerance will 
progress to DM223,28.  According to the American Diabetes Association, 70% of people with 
prediabetes will progress to diabetes. Globally, it is expected that there will be 398 million 
people with prediabetes by 203029.  
 
It has been now recognized that even non-diabetic levels of hyperglycemia, including impaired 
fasting glucose, and impaired glucose tolerance are associated with an elevated risk of CVD and 
premature mortality30-32. In the Diabetes Epidemiology: Collaborative Analysis of Diagnostic 
criteria in Europe (DECODE), the all-cause mortality and CVD mortality was higher in 
individuals with impaired glucose tolerance, independent of impaired fasting glucose (HR 1.73 
(1.45-2.06) for all causes, 1.40 (1.02-1.92) for cardiovascular disease, 1.56 (1.03-2.36) for 
coronary heart disease, and 1.29 (0.66-2.54) for stroke mortality)30. Coutinho et al. showed that 
IFG (≥6.1 mmol/L) was associated with both fatal and non-fatal CVD events. Significantly, they 
reported that even a 1 mmol/L rise in fasting blood glucose was associated with an increased risk 
of cardiovascular outcomes (RR = 1.09)32. The significance of the relationship between elevated 
fasting blood glucose and incidence of cardiovascular diseases persisted, even after adjusting for 
diabetic status33. In a large population-based cohort study, both IGT and IFG have been shown to 
be a predictor of premature mortality. People with known diabetes (type 1 and 2), impaired 
fasting glucose, and impaired glucose tolerance have a greater five-year mortality rate than those 
with normal glucose tolerance34.  
 
In the Whitehall study, London-based male civil servants between forty and sixty-four years of 
age were studied prospectively over thirty-three years to examine the relationship between high 
glucose after meals and mortality from coronary artery disease. Participants were given a 50-
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gram oral glucose tolerance test.  Those with 2-hour blood glucose levels ≥11.1 mmol/L were 
classified as a newly diagnosed diabetic group. Participants with a 2-hour blood glucose > 5.3–
11.0 mmol/L were classified as glucose intolerant, and, those below this level were classified as 
normoglycemic. Median survival differed by four years between the normoglycemic and 
glucose intolerant groups, showing that even glucose intolerance before the development of 
diabetes can increase the risk of cardiovascular complications35. Prediabetes has also been 
associated with microvascular complications like retinopathy, microalbuminuria, and 
neuropathy36-41. 
 
Once DM2 is diagnosed, it is well known that people may already have complications due to its 
often-silent presentation and unsuspected sustained hyperglycemia. The asymptomatic stage 
(high insulin resistance) and the stage of mild postprandial hyperglycemia are significant 
markers for patients at risk of developing diabetes. It is important to identify those high-risk 
people from millions of prediabetic cases, and to determine who will benefit most from the 
pharmacological interventions to prevent DM2. Patients who have sub-clinical inflammation 
could be at highest risk of converting from IR to DM2 and may benefit from pharmacological 
intervention to prevent the progression of insulin resistance42.  
 
 
2.4 Pathogenesis of Insulin Resistance 
 
Insulin is a peptide hormone. It is secreted by the β cells of the pancreatic islets of Langerhans. 
The major function of insulin is to maintain normal blood glucose levels. Insulin regulates the 
metabolism of carbohydrates, amino acids, and lipids43. Insulin exerts its effects predominately 
in the liver, muscle, and adipose tissue where it binds the cell surface insulin receptor. This 
triggers a signaling cascade that promotes anabolic metabolism and glucose uptake for cellular 
energy through the Kreb’s cycle. In the liver, insulin inhibits the production of glucose by 
inhibiting gluconeogenesis and glycogenolysis, and instead promotes the storage of glycogen. In 
muscle and fat tissue, insulin is anabolic resulting in adipose tissue stores of energy and protein 
synthesis to maintain muscle bulk44. 
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Insulin resistance is one of the acknowledged contributors in the pathogenesis of diabetes. It is 
defined as a subnormal biologic response to a given concentration of insulin45,46. IR can be 
measured indirectly by a ratio of fasting glucose and insulin levels. Higher ratios of insulin to 
glucose correspond to higher degrees of insulin resistance.  
 
Insulin resistance at the levels of muscle and liver are characteristic features of glucose 
intolerance in individuals with DM2. Insulin is needed to transport glucose to muscle and 
adipose tissue. Lack of insulin signaling at the muscle prevents the expression of glucose 
transporters and uptake of insulin from the blood stream47. In the basal state, the liver represents 
a major site of insulin resistance and failure of insulin signaling to turn off gluconeogenesis 
results in inappropriate overproduction of glucose despite the presence of high fasting insulin 
and glucose. Thus, the higher rate of glucose production by the liver is the primary determinant 
of high-fasting plasma glucose concentration. After glucose ingestion, both decreased muscle 
glucose uptake and impaired suppression of hepatic glucose production contribute to insulin 
resistance48.  
 
2.5 Etiology of Insulin Resistance  
 
Multiple causes of insulin resistance have been identified, many of which are reversible. The 
causes of the IR vary from lifestyle modification to the defect in genes important for insulin 
action. Specific hormonal or metabolic factors such as excess glucocorticoids (both exogenous 
and endogenous), excess growth hormone such as acromegaly, catecholamine excess, and excess 
glucagon can also cause IR. Other common reversible causes that are related to inflammation 
such as fever, sepsis, and infection are associated with IR.  
 
Environmental factors have been emerging as contributing factors for insulin resistance as well.  
Interestingly, the prevalence of IR increases as ethnic groups migrate from a less-developed area 
of the world to more urban and westernized regions. The prevalence of DM2 is four times higher 
in Japanese Americans in Seattle than Japanese citizens in Tokyo. Japanese American men with 
DM2 had significantly higher level of plasma insulin for the same level of hyperglycemia during 
75- gram oral glucose tolerance test. This effect persists even after adjusting for BMI, suggesting 
that there are more factors responsible for insulin resistance other than BMI and ethnicity50,51. 
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Currently, inflammation is emerging as one of the causes of IR, which will be discussed in more 
detail later in this chapter. 
 
Insulin resistance, even before the development of diabetes, can increase the risk of 
cardiovascular diseases. Significant associations between insulin resistance (measured by 
HOMAIR) and subsequent risk of CVD outcomes have been demonstrated in a large population-
based study. These associations remain even after adjustment for multiple potential confounding 
variables. Additionally, the study demonstrated that IR increased the risk of CVD independent of 
other risk factors and that waist circumference was not a significant variable in a multivariate 
analysis. This study also suggested that IR increased CVD risk independent of central adiposity 
and there was no significant evidence of effect modification by adiposity, glucose tolerance 
status, dyslipidemia, hypertension, ethnicity, or sex52.  
 
2.6 Methods to Measure Insulin Resistance 
 
Mathews et al. described the Homeostatic Model Assessment (HOMA) of beta cell function and 
insulin resistance in 198547. It is a computer-generated model of insulin/glucose interactions and 
used to plot an array of fasting plasma insulin and glucose concentrations that would be expected 
for varying degrees of beta cell deficiency and insulin resistance. These HOMA estimates have 
been compared with other estimates from other models like a euglycaemic hyperinsulinaemic 
clamp, hyperglycaemic clamp, and continuous infusion of glucose with model assessment 
(CIGMA)53-55. 
 
Although the hyperinsulinemic euglycemic clamp is referred to as the gold standard test for 
insulin sensitivity, the correlation between estimates of insulin resistance derived from HOMA 
and from the euglycemic clamp (Rs 0.88, p< 0.0001) is generally consistent53-55.  When 
measured, the median insulin resistance in normal subjects was 1.21 by HOMA and 1.45 by 
euglycaemic clamp, while in diabetic subjects it was 2.89 by HOMA and 4.1 by euglycaemic 
clamp53-55. HOMA has shown a good correlation with various other models as well 
(Hyperglycemic clamp Rs 0.69, p < 0.01, CIGMA Rs = 0.87, p < 0.0001, Minimal Model Rs 0.7, 
p<0.001). (Appendix A). 
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Due to the invasiveness of the insulin clamp and the technical difficulty in performing the test, 
HOMAIR has been widely used in epidemiological studies to quantitate insulin resistance. It is 
calculated by dividing the product of fasting insulin and glucose (SI units) by 22.555. HOMA 
analysis allows for the assessment of inherent beta cell function and insulin sensitivity and can 
characterize the pathophysiology in those with abnormal glucose tolerance. The use of HOMA to 
make comparisons across ethnic groups is valid, but the baseline HOMA from a normal 
glycemic population in each comparative group should be established first to determine whether 
a difference in insulin sensitivity between groups reflects a different baseline.  
 
2.7 Thresholds for HOMAIR 
 
HOMAIR is an effective tool to measure insulin resistance53-55. However, the threshold of how 
HOMAIR has been reported across different studies has been inconsistent. The difference in the 
threshold of HOMAIR levels can be explained by different clinical criteria used for insulin 
resistance and diversity in the specific population studied. Population-based studies have been 
conducted in different populations and in different world regions to define the threshold of 
HOMAIR. However, to our knowledge, no population-based study has defined the threshold of 
HOMAIR in the Canadian population.  
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2.8.1 Summary of Population Based Studies Defining the Threshold of HOMAIR 
 
 
 Study Population Definition of IR by 
HOMAIR 
Enzo et al.56 Northeastern Italy 
Non-diabetic 
90th percentile at 2.77 
 
Jing et al. 57 US population 
Non-diabetic 
75th percentile at 2.86 
Bruno et al. 58 Brazilian population 
Non-diabetic 
90th percentile at 2.71 
Ascaso et al.59 Spanish population 
Non-diabetic 
90th percentile at 3.8 
Pilar et al.60 Spanish population 
Non-diabetic 
75th percentile at 2.48 
Hedblad et al.61 Malmo, Sweden 
Non-diabetic 
75th percentile at 2.0 
Marques et al. 62 South-western France  
Both diabetic and non-diabetic  
75th percentile at 3.8 
Radikova et al. 63 Rural Caucasian population 
Non-diabetic 
75th percentile at 2.29 
Chizumi et al. 64 Japanese healthy population  
Non-diabetic 
Using Clinical and 
Laboratory Standards 
Institute definition of 
reference interval – 2.5 
 
 
 
Enzo Bonora, Stefan Kiechl, Johann Willeit, Friederich Oberhollenzer, Georg Egger, 
Giovanni Targher, Maria Alberiche, Riccardo C. Bonadonna, and Michele Muggeo, 
12 
 
Prevalence of Insulin Resistance in Metabolic Disorders, The Bruneck Study DIABETES, 
VOL. 47, OCTOBER 1998 
 
In this study, subjects (n=225) who do not have a metabolic disorder and BMI ≤25 kg/m2 were 
included. Subjects were divided into the five quintiles were as follows: 0.19–1.11, 1.12–1.54, 
1.55–2.03, 2.04–2.76, and 2.77–36.4. The presence of insulin resistance was defined as 
HOMAIR in the lower limit of the top quintile 90th percentile (i.e., 2.77) 
 
Jing Chen, Rachel P. Wildman, L. Lee Hamm,Paul Muntner, Kristi Reynolds, Paul K. 
Whelton, Jiang He, Association Between Inflammation and Insulin Resistance in U.S. 
Nondiabetic Adults Results from the Third National Health and Nutrition Examination 
Survey Diabetes Care 27:2960 –2968, 2004 
National Health and Nutrition Examination Survey (NHANES) III was conducted by the 
National Center for Health Statistics of the Centers for Disease Control and Prevention between 
1988 and 1994.  The top 25th percentile was compared with the bottom 75th percentile (2.86 vs. 
2.86)  
 
Summer AE, Cowie CC. Ethnic differences in the ability of triglyceride levels to identify 
insulin resistance. Atherosclerosis. 2008; 196:696-703 
 
Summer et al. performed a study utilizing the National Health and Nutrition Examination Survey 
1999–2002, to determine the prevalence of each of the metabolic syndromes and the ability of 
fasting triglycerides concentrations to identify insulin resistance by ethnicity. Participants were 
2804 adults from NHANES 1999–2002. The cohort was divided into tertiles of homeostasis 
model assessment. Insulin resistance was defined as the upper tertile (≥2.73). 
 
Bruno Geloneze, Ana Carolina Junqueira Vasques, Christiane França Camargo Stabe, 
José Carlos Pareja, Lina Enriqueta Frandsen Paez de Lima Rosado, Elaine Cristina de 
Queiroz, Marcos Antonio Tambascia, BRAMS Investigators HOMA1-IR and HOMA2-IR 
indexes in identifying insulin resistance and metabolic syndrome – Brazilian Metabolic 
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Syndrome Study (BRAMS) Arq Bras Endocrinol Metab. 2009;53/2 
In this study, insulin sensitivity was assessed in normal subjects without any known risk factors 
for insulin resistance sampled from those of the Brazilian Metabolic Syndrome Study (BRAMS). 
BRAMS was a population-based survey of metabolic disorders, insulin resistance was measured 
in normal adults without any known risk factor. This study included 1317 subjects (976 women, 
341 men), age: 40((±12 years), BMI: 34((±10 kg/m2). Insulin resistance (HOMAIR) was defined 
as at 90th percentile (2.71). 
 
 
Ascaso JF, Romero P, Real JT, Priego A, Valdecabres C, Carmena R. Insulin resistance 
quantification by fasting insulin plasma values and HOMA index in a non-diabetic 
population Diabetes Care. 2000 Feb;23(2):171-5 
 
Ascaso et al. studied 292 non-diabetic individuals, aged between twenty and sixty-five years. 97 
subjects who lacked clinical and biological criteria of insulin resistance were selected. In this 
subgroup of ninety-seven subjects without clinical and biological criteria of IR, the diagnosis of 
IR was established when the HOMA index was >= 3.8 (cut off at 90th percentile). The prevalence 
of insulin resistance (HOMA >= 3.8) was 31.8%, with a higher frequency in men compared to 
women. 
 
Pilar Gayoso-Diz, Alfonso Otero-Gonzalez, Marı ́a Xose ́ Rodriguez-Alvarez, Francisco 
Gude, Carmen Cadarso-Suarez, Fernando Garcı ́a, Angel De Francisco. Insulin resistance 
index (HOMAIR) levels in a general adult population: Curves percentile by gender and 
age. The EPIRCE study: Diabetes research and clinical practice 94 (2011) 146–155 
The EPIRCE was an epidemiologic, cross-sectional population-based study that included a 
randomly selected sample of Spanish persons aged twenty years and older. 2246 individuals 
without diabetes were included for analysis. Mean Observed HOMAIR levels were higher in 
men than in women (2.06 vs. 1.93, respectively; P = 0.047). The distribution of HOMAIR was 
different in men and women in different decades of age. Observed HOMAIR at 75th percentile 
was 2.48 for the study population. For the population in this study, HOMAIR at 75th percentile 
for men was 2.88 and for women was 2.35. Women aged over fifty had significantly higher 
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HOMAIR levels (P for trend = 0.04). Whereas in men there was no association between age and 
HOMAIR.  
Hedblad B, Nilsson P, Janzon L, Berglund G. Relation between insulin resistance and 
carotid intima-media thickness and stenosis in non-diabetic subjects. Results from a cross-
sectional study in Malmo, Sweden. Diabet Med. 2000; 17:299-307 
This was cross-sectional population-based study in Malmo, Sweden. Non-diabetic subjects were 
selected to assess the relationship between insulin resistance and carotid intima-media thickness. 
Insulin resistance (HOMAIR) defined at values exceeding 2.0 (75th percentile). Insulin resistance 
syndrome was defined by the presence of insulin resistance or fasting hyperinsulinemia in 
combination with at least two of the following conditions: hyperglycemia, hypertension, 
dyslipidemia, and/or central obesity. Age, sex and ethnicity were not taken into consideration to 
define the threshold of HOMAIR.  
Marques-Vidal P, Mazoyer E, Bongard V, Gourdy P, Ruidavets JB, Drouet L, Ferrières J. 
Prevalence of insulin resistance syndrome in Southwestern France and its relationship with 
inflammatory and haemostatic markers. Diabetes Care. 2002; 25:1371-1377. 
In a cross-sectional study done on a representative sample of the population in southwestern 
France aged thirty-five to sixty-four years, data was collected from 597 men and 556 women. 
Both diabetic and non-diabetic participants were included. Only subjects on insulin therapy were 
excluded. A HOMAIR cut off of 3.8 was used as one of the components of insulin resistance 
syndrome. The prevalence of insulin resistance syndrome was higher in men than women, but 
decreased with advancing age.  
Radikova Z, Koska J, Huckova M, Ksinantova L, Imrich R, Vigas M, Trnovec T, Langer 
P, Sebokova E, Klimes I. Insulin sensitivity indices: A proposal of cut-off points for simple 
identification of insulin-resistant subjects. Exp Clin Endocrinol Diabetes. 2006; 114:249-
256. 
A study was done using 1156 subjects from a Caucasian rural population with no previous 
evidence of diabetes to define the cut off of insulin resistance. A 75-g oral glucose tolerance test 
was administered.  HOMAIR of 2.29 (75th percentile) was used as the cut off point to define 
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insulin resistance 
Esteghamati A, Ashraf H, Khalilzadeh O, Zandieh A, Nakhjavani M, Rashidi A, Haghazali 
M, Asgari F. Optimal cut-off of homeostasis model assessment of insulin resistance 
(HOMAIR) for the diagnosis of metabolic syndrome: Third national surveillance of risk 
factors of non-communicable diseases in Iran, Nutr Metab (Lond). 2010; 7:7-26. 
To establish the cut-off insulin resistance in the Iranian population with or without diabetes, a 
study was conducted based on the third National Surveillance of Risk Factors of Non-
Communicable Diseases. The results for 3,071 adult Iranian individuals aged twenty-five to 
sixty-four years were analyzed. The threshold of HOMAIR for the diagnosis of metabolic 
syndrome was estimated to be 1.77 in non-diabetics and 4.00 in diabetic patients. 
Chizumi Yamada, Toshitake Mitsuhashi, Noboru Hiratsuka, Fumiyo Inabe, Nami 
Araida, and Eiko Takahashi Optimal reference interval for homeostasis model assessment 
of insulin resistance in a Japanese population. J Diabetes Investigation. 2011 Oct 7; 2(5): 
373–376. 
A study was done to determine a threshold for homeostasis model assessment of insulin 
resistance (HOMAIR) in a Japanese population. Healthy subjects aged twenty to seventy-nine 
years with normal fasting plasma glucose and a body mass index < 25 kg/m2 were selected. 2173 
subjects were used as reference individuals, and 2153 subjects were used for analysis. It was 
determined that a HOMAIR of 2.5 should be considered a reasonable indicator of insulin 
resistance in Japanese population.  
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CHAPTER THREE: INFLAMMATION AND INSULIN RESISTANCE 
______________________________________________________________________________ 
 
3.1 Inflammation and Inflammatory Markers 
 
The presence of low-grade inflammation in multiple chronic conditions is well documented. In 
cases of low-grade inflammation, classic clinical signs of inflammation are absent and only a 
minor degree of elevation in inflammatory markers are present when tested. This is different 
from acute inflammation and can occur in various chronic and metabolic conditions65,66. 
Epidemiological studies show that minor degrees of multiple serum inflammatory markers are 
elevated,  are present in a high proportion of the population, and are associated with various 
lifestyle choices and medical conditions67,68. Multiple medical conditions, such as atrial 
fibrillation, hypertension, hypertriglyceridemia, and high blood pressure, that are not 
inflammatory, are associated with a minor elevation of C-reactive protein68. Smoking can cause 
mild elevation in CRP69. Exercise does not have anti-inflammatory effect immediately. However, 
it can have anti-inflammatory effects over the long term70. Moderate alcohol intake has been 
shown to reduce CRP71. 
Several bio-markers linked to inflammation have been identified and validated, and various other 
markers are being investigated. However, no one single inflammatory marker is a perfect 
measure. An increase in the concentration of these biomarkers, called acute phase reactants, 
correlates with tissue injury and inflammation. Although referred to as acute phase reactants, it 
represents inflammation in both acute and chronic conditions72-74. In current clinical practice, 
CRP is the most widely used inflammatory marker employed to monitor acute phase response 
and used to follow the activity of infections, inflammatory disorders, and tissue damage.  It is 
also considered a valuable marker of low grade, chronic inflammation75. CRP is an acute phase 
reactant and a marker of systemic inflammation. It is regarded as an early indicator of infection 
or inflammation. A normal healthy subject has a median CRP level of 0.8mg/L. CRP is produced 
by hepatocytes, and its synthesis is regulated by pro-inflammatory cytokines, specifically, 
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interleukin-6. CRP shows little short-term fluctuation which makes it particularly useful to 
follow. 
 
In recent studies, approximately 70–90% of samples from multiple reference populations had 
CRP concentrations less than 3 mg/L. This suggests that normal levels in the American 
population are less than 3 mg/L76. The plasma half-life of CRP is nineteen hours. When 
compared between normal healthy controls and people with disease, there was no difference in 
the turnover rate or body clearance of CRP. This indicates that there was no accumulation of 
CRP in people with cardiovascular disease to explain the higher levels of CRP correlated with 
CVD77. 
After the original reports noting that CRP elevation was associated with increased CVD, 
additional highly sensitive assays were developed to accurately quantitate the relatively low 
concentration of CRP found in healthy populations78. Traditionally, CRP levels were measured 
in the laboratories to detect concentrations up to 3mg/L. However, this did not have enough 
sensitivity to quantify low values in otherwise healthy men and women. Later, more-sensitive 
techniques were developed to measure low levels of CRP (high-sensitivity CRP; hs-CRP) to 
attain the desired quantification. Now, hs-CRP concentrations as low as 0.15 mg/L can be 
reliably measured79. CRP levels are unaffected by the gender and age of the patient80.  
We have included hs-CRP as a marker of inflammation as it is the most widely used 
inflammatory marker in current clinical practice due to it stability, availability, and low cost. We 
have divided CRP measurement into a dichotomous variable with the cut off of 3mg/L for the 
convenience of clinical interpretation.  
 
3.2 Inflammation and Diabetes 
 
More recently, chronic inflammation has emerged as an independent risk factor for the 
development of type 2 diabetes. Chronic subclinical inflammation is known to down-regulate 
major anabolic cascades by the release of cytokines involved in modulating insulin signaling and 
in turn promote insulin resistance in adipose, muscle, and hepatic tissues. This global insulin 
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resistance likely impairs the whole-body insulin sensitivity and causes IR81. Current evidence 
supports the idea that inflammation has an important role in the pathogenesis of DM2. The odds 
of developing diabetes are higher in people who have higher baseline inflammatory markers82. 
 
Chronic inflammation has long been associated with DM2, but it is unknown if it is a cause or an 
effect of this metabolic disturbance. A clue to the relationship between inflammation and 
diabetes dates back more than a century when high doses of salicylates (anti-inflammatory 
drugs) were seen to reduce glucose in the urine of diabetic patients. In 1876, Ebstein determined 
that sodium salicylate improved the symptoms of diabetes mellitus83,84. A similar effect was 
found later in 1901 by Williamson85. Later, Gross and Greenberg cited fifteen clinical reports on 
the beneficial effects of salicylates on lowering glucose levels86.  
In 1957, Reid and colleagues noticed that when insulin-dependent diabetic patients with 
rheumatic fever associated arthritis were given high doses of aspirin for their treatment, they no 
longer required insulin injections87. This effect persisted until the aspirin was discontinued. 
Salicylates are non-steroidal anti-inflammatory agents and can improve glucose control. 
Compared with placebo, salicylate have been shown to decrease fasting glucose by 13% (P < 
0.002), CRP by 34% (P < 0.05) and glycated albumin by 17% (P < 0.0003) and can improve 
insulin sensitivity88,89. These early studies showed that salicylates not only improves blood 
glucose at higher doses, but also do not induce hypoglycemia. Unfortunately, high doses of 
salicylates are associated with several adverse side effects including: tinnitus, anorexia, nausea, 
and vomiting. Moreover, nausea and vomiting can cause starvation ketosis, which can be 
confused with diabetes ketosis, and might have led to discontinuing the use of salicylates90,91.  
 
3.2.1 C - reactive protein – Predictor of Diabetes and Cardiovascular Disease 
 
High-sensitivity C-reactive protein and tumor necrosis factor alpha are present in individuals 
with prediabetes, and have been shown to predict the development of diabetes92-94. Pradhan et al. 
showed that CRP was an independent predictor of cardiovascular diseases after adjustment for 
body mass index (BMI), clinical risk factors, and fasting insulin levels in women. In this study, 
an association was found with interleukin-6, though of borderline statistical significance after 
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multivariate analysis. Baseline levels of IL-6 (p<0.001) and CRP (P< 0.001) were significantly 
higher among people who developed diabetes than those who did not develop diabetes. The 
relative risk of developing diabetes for women was 15.7 (95%CI, 6.5-37.9) for highest vs. lower 
quartile. The association persisted after adjusting for other contributors94.  
 
Baseline plasma C-reactive protein in a healthy individual can predict the risk of myocardial 
infarction, ischemic stroke, and diabetes95-99. CRP has been proven to have several advantages in 
the detection and monitoring of atherosclerosis and its complications. Use of CRP in several 
nested case-control studies in initially healthy subjects has shown an association between 
baseline CRP and cardiovascular outcomes97, 100, 101.  The West of Scotland Coronary Prevention 
Study (WOSCOPS) found that C-reactive protein predicted the development of DM2 in middle-
aged men independently of established risk factors102.  
CRP has proven to be a strong independent predictor of both incidents of diabetes and 
cardiovascular disease. It was found to have a linear increase in the incident of diabetes with 
increasing quartiles of CRP (6.9, 12.1, 16.2, and 19.9% in quartiles 1–4, respectively and was 
statistically significant (p= 0.001). The similar association was found for PAI-1. This relation 
was consistent in men and women, in lean and obese subjects, and across a different ethnic 
group67, 94, 103.  
 
Most hypoglycemic agents used to treat diabetes have an independent beneficial effect on 
inflammation. Extensive studies have been carried out with metformin, which demonstrated a 
moderate to strong anti-inflammatory response. Metformin is also known to lower fasting plasma 
glucose by decreasing hepatic glucose production and improving muscle insulin sensitivity104. 
Metformin can reduce the production of the pro-inflammatory cytokines interleukin IL-1, IL-6 
and tumor necrosis factor (TNF)74,105. Evidence suggested that thiazolidinedione (TZD) therapy 
had an anti-inflammatory effect that can explain its favorable effect on inflammatory states in 
patients with DM2106-110. Other studies have shown the beneficial effect of other hypoglycemic 
agents, for example, dipeptidyl peptidase-4 inhibitors and Sulfonylureas, on inflammation111-117.  
 
20 
 
3.2.2 Previous Studies with Insulin Resistance and Inflammation in Selected Communities 
 
 
It has been hypothesized that chronic inflammation could be the trigger for insulin resistance and 
eventually DM2, as suggested by Pick and Crook in 1998118. 
Bizu Gelaye, Luis Revilla, Tania Lopez, Luis Suarez, Sixto E Sanchez, Karin Hevner, 
Annette L Fitzpatrick and Michelle a Williams, Association between insulin resistance 
and c-reactive protein among Peruvian adults, Diabetology & Metabolic Syndrome 
2010, 2:30 
 
Peruvian men and women who participated in the FRENT study, (Prevalence of Risk Factors for 
Non-Transmissible Diseases) were part of this large epidemiological study. There were 1,525 
participants (569 men and 956 women). Here, subjects with no history of diabetes were included. 
As lipid lowering medications can reduce CRP, those medications were excluded. Insulin 
resistance was measured by HOMAIR. CRP values were divided into three defined tertiles: 
<0.81 mg/L, 0.81- 2.53 mg/L, and >2.53 mg/L. <0.81 mg/L, 0.81- 2.53 mg/L, and >2.53 mg/L.  
Age, BMI, and current smoking status were adjusted within a multivariate model. Insulin 
resistance was defined when HOMAIR was in the highest quartile (HOMAIR > 5.12). Men had 
higher rates of current smoker, mean waist circumference, triglycerides, and systolic and 
diastolic blood pressure. Women had higher mean age, high density lipoprotein, total cholesterol, 
and low density lipoprotein. Values of CRP were positively associated with HOMAIR 
(p<0.001). After adjusting for all the covariates, the odd ratio of insulin resistance in each tertiles 
of CRP was 1.35 and 2.18 in men and 2.67 and 2.58 in women. Limitations of the study were 
that it did not control for waist circumference, cholesterol profile, acute or chronic conditions, or 
blood pressure.  
 
Pedro Marques-Vidal, Elizabeth Mazoyer, Vanina Bongard, Pierre Gourdy, Jean-
Bernard Ruidavets, Ludovic Drouet, Jean Ferrie`Res, Prevalence of Insulin 
Resistance Syndrome in Southwestern France and Its Relationship with Inflammatory 
and Hemostatic Markers Diabetes Care, Volume 25, Number 8, August 2002 
 
This was a cross-sectional study that included 597 men and 556 women. Subjects with HOMAIR 
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> 3.8 (lower level of the population upper quartile) were considered insulin resistant. Subjects on 
insulin therapy were excluded. Prevalence of IRS was higher in men than in women (23% vs. 
12%, respectively; P < 0.001) and increased with age in both sexes 
There was no difference in the age between men and women, however women had lower BMI, 
waist-hip ratio, blood pressure levels, total cholesterol and triglyceride levels, HOMA, insulin 
and higher HDL cholesterol, and fibrinogen than in men. After adjusting for age, alcohol 
consumption, smoking, and menopause, subjects with insulin resistance had significantly higher 
levels of CRP, white blood cell count, factor VII levels, coagulating factor VII levels. As the 
main objective of this study was to assess the prevalence of IRS in the general population of 
southwestern France, subjects with a history of hypertension, hypertriglyceridemia, or diabetes 
were not excluded from the analysis. 
John S. Yudkin, C.D.A. Stehouwer, J.J. Emeis, S.W. Coppack C-Reactive Protein in 
Healthy Subjects: Associations with Obesity, Insulin Resistance, and Endothelial 
Dysfunction a Potential Role for Cytokines Originating from Adipose Tissue? Arterioscler 
Thromb Vasc Biol. 1999; 19:972-978. 
Yudkin et al. looked at the association of C-reactive protein and interleukin-6 with the features of 
insulin resistance syndrome. They studied 107 non-diabetic adults aged forty to seventy-five 
years. Levels of C-reactive protein were significantly associated with interleukin-6 and tumor 
necrosis factor. C-reactive protein was associated with insulin resistance (HOMAIR), blood 
pressure, HDL, and triglyceride, markers of endothelial dysfunction (plasma levels of von 
Willebrand factor, tissue plasminogen activator, and cellular fibronectin).  
E. Ingelsson, J. Hulthe, and L. Lind,Inflammatory markers in relation to insulin 
resistance and the metabolic syndrome Eur J Clin Invest 2008; 38 
In the community of Uppsala, Sweden, between April 2001 and June 2004, all seventy-year-old 
(n=1016) individuals participated in the Prospective Investigation of the Vasculature in Uppsala 
Seniors (PIVUS) study. To account for acute or chronic infections and blood malignancies, 
participants with CRP > 10 mg L–1 or leukocyte count > 10 * 109 cells L–1 (n = 73) were 
excluded.  The study sample of 943 participants (50% women) were included for the analysis. 
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Various circulatory interleukins, tumor necrosis factor, intercellular adhesion molecule-1, and 
markers of systemic inflammation (CRP and leukocyte count) were measured. The multivariate 
model was adjusted for sex, oral glucose lowering medications, statins, and antihypertensive to 
examine the association between these bio-markers of inflammation and HOMAIR. Among 
seventeen inflammatory bio-markers, E-selection and CRP demonstrated the strongest 
relationship between inflammation and insulin resistance in seniors over the age of seventy.  
Andreas Festa, Ralph D'Agostino, Jr, George Howard, Leena Mykkänen, Russell P. 
Tracy and Steven M. Haffner Chronic Subclinical Inflammation as Part of the 
Insulin Resistance Syndrome: The Insulin Resistance Atherosclerosis Study (IRAS 
Circulation. 2000; 102:42-47 
 
The Insulin Resistance Atherosclerosis Study (IRAS) was a multicenter, population-based 
epidemiological study that examined the association between insulin resistance, cardiovascular 
risk factors, and cardiovascular disease across different ethnic groups and various states of 
glucose tolerance. As part of the IRAS, 1088 non-diabetic individuals, ages forty to sixty-nine 
years participated. A standard 75-g oral glucose tolerance test was performed. Insulin sensitivity 
was assessed by a frequently sampled intravenous glucose tolerance test with minimal model 
analysis. 33% of participants had impaired glucose tolerance. 
 
Any participant with a current acute illness and clinically overt coronary artery disease were 
excluded. People with clinically overt coronary artery disease and history of myocardial 
infarction were also excluded. The relationship of three inflammatory markers (CRP, Fibrinogen, 
and white blood cells) were examined with components of the metabolic syndrome. The 
multivariate model was adjusted for age, sex, ethnicity, clinic, and smoking status. In the model, 
interaction was also tested for BMI, insulin, and pro-insulin. All three inflammatory markers 
were related to the metabolic syndrome. However, the association was strongest for CRP as it 
showed that CRP was independently associated with insulin sensitivity.  
 
Andreas Festa; Anthony J.G. Hanley; Russell P. Tracy; Ralph D’Agostino; Steven M. 
Haffner, Inflammation in the Prediabetic State Is Related to Increased Insulin Resistance 
Rather Than Decreased Insulin Secretion, 
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Circulation. 2003; 108:1822-1830 
 
An additional cohort of 906 non-diabetic subjects, non-diabetic at baseline, were followed for 5.2 
years from the same population of IRAS. Subjects who developed diabetes during follow-up 
were defined as prediabetic, and those who remained non-diabetic were defined as non-
converters. A standard 75-g oral glucose tolerance test was performed. Insulin sensitivity was 
assessed by a frequently sampled intravenous glucose tolerance test with minimal model 
analysis. Prediabetic people had higher inflammatory markers at baseline than non-converters.  
Prediabetic individuals who were insulin resistant had higher CRP (mean [95% CI], 2.88 mg/L 
[2.33 to 3.56] versus 1.68 mg/L [1.13 to 2.49] than prediabetic subjects with high insulin 
sensitivity. It was shown that increased inflammatory markers in prediabetics are predominately 
related to insulin resistance and not with primary defect in beta cell dysfunction.  
 
Chen J, Wildman RP, Hamm LL, Muntner P, Reynolds K, Whelton PK, He J; Third 
National Health and Nutrition Examination Survey. Association between inflammation and 
insulin resistance in U.S. nondiabetic adults: results from the Third National Health and 
Nutrition Examination Survey. Diabetes Care. 2004 Dec; 27(12):2960-5 
 
The National Health and Nutrition Examination Survey (NHANES III) was conducted by the 
National Center for Health Statistics of the Centers for Disease Control and Prevention between 
1988 and 1994. A subsample of participants was randomly selected as a  fasting morning sample. 
Participants with a history of diabetes, abnormal fasting blood glucose, or who were using 
diabetic medications at the time were excluded. 5959 participants were included for the main 
analysis. HOMAIR was used to assess the participants’ insulin resistance. Elevated HOMAIR 
was defined as being in the upper 25th percentile (≥2.86). Multivariable models were adjusted 
for age, sex, race, education, physical activity, current and former smoker, NSAID use in the past 
month, alcohol intake, systolic blood pressure, BMI, waist circumference, serum total 
cholesterol, and triglycerides. The odds ratios of insulin resistance were calculated between 
detectable C-reactive protein (0.22–0.99 mg/dl), clinically elevated C-reactive protein (≥1.0 
mg/dl equivalent to 10mg/L), and undetectable C-reactive protein. The clinically elevated CRP 
(>1mg/dl) was associated with 0.63 (0.23-1.04, P=0.003) higher insulin resistance (measured by 
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HOMAIR) after adjusting for potential confounder. The association was consistent in both men 
and women. 
 
Maria Fizelova, Raimo Jauhiainen, Antti J. Kangas, Pasi Soininen, Mika Ala-Korpela, 
Johanna Kuusisto, Markku Laakso, and Alena Stancˇa ́kova ; Differential Associations of 
Inflammatory Markers with Insulin Sensitivity and Secretion: The Prospective METSIM 
Study, J Clin Endocrinol Metab 102: 3600–3609, 2017 
 
The Metabolic Syndrome in Men (METSIM) study included 10,197 Finnish middle-aged men  
The baseline study was performed from 2005 to 2010. A subset of  8749 men without type 2 
diabetes at baseline were selected to examine the association between markers of inflammation 
(glycoprotein acetyls (GlycA), interleukin-1 receptor antagonist, and C-reactive protein) with 
insulin secretion, insulin sensitivity, and incident type 2 diabetes. Glucose tolerance was done 
using a 2-hour oral glucose tolerance test (OGTT) with 75- g of glucose. Men with history of 
diabetes were excluded. CRP levels were associated with insulin sensitivity (Hazard ratio, 1.13; 
95% confidence interval, 1.07 to 1.20). 
 
Martin K. Rutter; James B. Meigs; Lisa M. Sullivan; Ralph B. D’Agostino; Peter W.F. 
Wilson; C-Reactive Protein, the Metabolic Syndrome, and Prediction of Cardiovascular 
Events in the Framingham Offspring Study. Circulation. 2004; 110:380-385 
 
The Framingham Offspring Study was a community-based observational study that examined the 
risk factors for cardiovascular disease. Participants from this study were selected from cycle five 
(January 1991 through 1995) to examine the association of inflammation with metabolic 
syndrome and cardiovascular disease. 3037 Participants who did not have history of diabetes or 
prevalent cardiovascular disease were included for analysis. Insulin resistance was assessed 
through the use of HOMAIR. The multivariable model was adjusted for age and sex. It was 
found that HOMAIR was higher in men than in women. Moreover, both C-reactive protein (HR, 
1.8; 95% CI 1.4-2.5) and metabolic syndrome (HR, 1.9; 95% CI, 1.2-2.9) were independent risk 
factors for cardiovascular diseases, even after adjusting for age and sex.  
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CHAPTER FOUR: STUDY METHODOLOGY 
______________________________________________________________________________ 
 
4.1 Canadian Health Measure Survey (CHMS) 
 
The Canadian Health Measure Survey has been developed by Statistics Canada to measure the 
indicators of health and wellness of Canadians. They began collecting data in 2007119. 
Originally, a representative sample of around 5000 Canadians, aged six to seventy-nine years 
was selected. The data from cycle one to four has been released to the Research Data Centre by 
Statistics Canada. At the time of this analysis, cycle one, two, and three were available and used 
as part of this study. (Appendix C). 
 
Data collection for the CHMS takes place every two years119. The CHMS is conducted in two 
steps. First, an interviewer visits the respondents’ home and administers a household 
questionnaire. Second, the respondents visit a mobile health clinic where trained medical staff 
take direct physical health measures. In the mobile health clinic, blood is drawn for laboratory 
investigations and a urine sample is collected for analysis120. 
 
The CHMS developed a conceptual framework to include all important measures that would 
allow for a comprehensive assessment of individual and group health. The conceptual framework 
diagram (Appendix B)119 illustrates the importance of measuring non-individual level variables 
that may serve as important moderators of individual health indicators. One of the key 
component of the CHMS is a direct measure of physical health. Health information collected 
through self-reported surveys or administrative records may be incomplete or inaccurate as many 
variables cannot be determined in the absence of direct physical measures. The clinical team 
consists of a manager, a health measure specialist that administers most of the physical tests 
(blood pressure, anthropometry, fitness testing and spirometry, etc.), and a laboratory technician 
or technologist who performs the phlebotomy as well as processes the bio-specimens for storage 
and shipment to the reference laboratories.  Staff are selected based on the level of education, 
experience, and certification(s) required for each position. In addition, a significant amount of 
survey-specific training is provided to all field staff, emphasizing quality control guidelines and 
the need for standardization of all survey procedures. The CHMS has four components: The 
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Household Component, the Mobile Examination Centre, the Laboratory Component, and the 
Biobank Component. 
 
4.1.1 Household Component 
 
The household component includes a detailed questionnaire which takes participants 
approximately seventy-five minutes to complete121.  Interviewers ask participants a variety of 
questions about their health and living situation, including:  
• Identifying any known acute or chronic conditions.  
• Information on food and nutrition status.  
• Environmental and socioeconomic information. 
• General health-related questions. 
The interviewer’s questions are arranged to accommodate for computer-assisted personal 
interviewing (CAPI)120.  The advantage to using CAPI in this extensive national study is that it 
provides interviewers with tools to exclude out of range values and helped limit flow errors by 
ensuring that questions that do not apply to the respondents are excluded and that inconsistent 
reporting by participants was identified.  
 
4.1.2 Mobile Examination Center (MEC) 
 
When the household interview is complete, the interviewer provides the respondent with 
guidelines and timelines for attending and participating in the physical examination component 
of the CHMS121. This step is in part based on the successful use of mobile examination centers in 
the NHANES in the US121. These guidelines are to ensure standardization, and it is essential to 
the accuracy and credibility of the study that the guidelines are followed as closely as possible. 
Each visit lasts for approximately two hours. At the beginning of the physical examination, 
examiners ensure that participants are following the pre-examination guidelines prior to 
continuing. During the examination, physical measurements that are taken may include: 
anthropometric, cardiovascular, and musculoskeletal fitness measures, physical activity, oral 
health (cycle one only), spirometry, and biological specimens. 
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4.1.3 Laboratory Component 
 
Most biological samples collected at the mobile examination center are processed (e.g; 
centrifuged, aliquoted) before they are shipped to the reference laboratories, with the exception 
of DNA. The sole test completed on site is a complete blood count, all other blood and urine 
samples are sent to one of three laboratories for analysis. These laboratories include: Health 
Canada Laboratory, Bureau of Nutritional Sciences Nutrition Research Division, National 
Microbiology Laboratory, and L’Institut de Sante Publique du Quebec. Participants’s blood 
samples are measured for diabetes, cardiovascular health, infectious disease markers, nutritional 
information, and other general information. 
 
4.1.4 Biobank Component 
 
For the purposes of record-keeping and future study, blood, urine and other bio-specimens which 
are collected during the CHMS from consenting participants were stored at the CHMS 
Biobank located at the National Microbiology Laboratory in Winnipeg. 
 
4.1.5 Sampling Methodology  
 
The sample methodology differs depending on the cycle. Generally, the CHMS targets 
individuals aged three to seventy-nine years that live in private homes. The study selects 
respondents equally by age group and sex. Collection sites are spread across five regions to 
ensure that all Canadian regions are represented. These regions include: British Columbia, the 
Prairies, Ontario, Quebec, and the Atlantic provinces.  The amount of collection sites within each 
region differs depending on the cycle, as does the total number of respondents.  
 
4.1.6 Estimation and Quality Control 
 
Each person taking part in the final survey is assigned a survey weigh122.  This weight is a 
proportional representation of that person to their corresponding members of the Canadian 
population. When inferring an estimate from this study, it is imperative that the survey weight is 
used in order for the estimate to be representative of the population. If it is not used, then it only 
represents the survey sample. 
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For the purposes of accuracy and quality assurance, interviewers received extensive training 
from Statistics Canada and were provided with comprehensive information manuals. 
Furthermore, interviews received regular oversight. This was to ensure strict adherence to 
protocol, and to protect the quality of data collection and interaction with participants. When 
needed, experts observed and evaluated staff to ensure rigorous levels of testing and record 
keeping.  In cases where participants refused to answer questions, managers followed-up to 
encourage participation.  If the participant maintained a position of non-response then the final 
weight of the household was modified to accommodate for that non-response122.  
Statistics Canada received Research Ethics Board approval for the CHMS. Participation is 
voluntary and participants are able to decline to answer any specific question or participate in 
any specific measure. They can also decline to receive lab results, participate in the measurement 
and reporting of reportable diseases, and in the storage of their DNA. The collection for the first 
cycle for CHMS began in 2007. Planning up to cycle eight is currently underway. Dissemination 
for a cycle usually begins ten months after the end of the cycle’s collection period. CHMS cycles 
one, two, and three were available for this thesis. 
 
Despite the efforts to maintain a high degree of accuracy, the estimates will be subject to a small 
degree of non-sampling error. This may occur because of non-response, population coverage, 
differences in the interpretations of questions, and errors in recording, and coding and processing 
data.  
 
4.1.7 Fasted Sub-Sample 
 
For the fasted subsample, each household is randomly identified as to whether a respondent 
should fast or not prior to their appointment. Those that are flagged for fasting need to do so for 
ten hours prior to their appointment. However, those households that are not flagged have less 
severe eating restrictions placed on them. In household where pregnant women, people with 
diabetes, children less than six years old, and where other special cases were present, fasting is 
not required, even if it has been identified a fasting household. This random identification of 
households is intended to prevent bias. For the final collection of survey results, rates are 
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adjusted so that 50% of respondents are from fasting households and 50% are from non-fasting 
households.  
 
4.1.8 Cycle One (C1) (March 2007 to March 2009) 
 
 
The target population for the first cycle of the CHMS included individuals between six and 
seventy-nine years of age. The sample was allocated over ten age/gender groups, and 500 units 
per group were required to produce usable national estimates. In total, there were 5,000 reporting 
units123. Data collection for this reference period took place from March 1st, 2007 through March 
31st, 2009. 257 sites were created, including two sites in the Territories. These sites were spread 
across the five regions of Canada. It was decided that a sample of fifteen collection sites was 
required. These sites have been allocated by region in proportion to their populations: Atlantic 
(1), Quebec (4), Ontario (6), Prairies (2) and British Columbia (2). Approximately 350 reporting 
units per sites participated in all parts of the survey. 
 
 
4.1.9 Cycle Two (C2) (August 2009 to November 2011) 
 
 
During the second cycle, the CHMS included participants aged three to seventy-nine years. For 
this cycle, individuals living on reserves and other Aboriginal settlements, members of the 
Canadian Forces, the institutionalized population, and certain other residents were excluded. The 
data collection for this cycle was from August 8th, 2009 through to November 30th, 2011. The 
sample was allocated over eleven age/gender groups, with 500 to 600 units per group (5,700 
total) required to produce usable national estimates124. 257 sites were created, including two sites 
in the Territories. These various sites were spread across the five Canadian regions. In this case, 
eighteen sites were created in these five regions. They were allocated as follows: Atlantic (2), 
Quebec (4), Ontario (6), Prairies (3) and British Columbia (3). Sites were randomly selected 
using a systematic sampling method with probability proportional to the size of each site's 
population. There were approximately 350 reporting units per site that participated in all parts of 
the survey. There was a total of 6,400 participants across all sites124. 
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4.1.10 Cycle Three (C3) (January 2012 to December 2013) 
 
The target population for the third cycle consisted of persons aged three to seventy-nine years. 
Data collection for this reference period began on September 1st, 2009 and ended on December 
17th, 2013125.  The sample was allocated over eleven age/gender groups. To produce national 
estimates, groups with between 500 to 600 units were required. It was estimated that sample size 
of 5,700 was needed to yield usable national results. Like previous cycles, sites were stratified 
based on the five Canadian regions. Sixteen sites were created within the five regions. The sites 
were allocated by region as follows: Atlantic (2), Quebec (4), Ontario (6), Prairies (2) and British 
Columbia (2). 
 
 
4.4 Inclusion Criteria 
 
1. Fasted subsample from three CHMS cycles. 
2. Age eighteen and older. 
3. Fasted insulin and glucose available (all three cycles). 
 
4.5 Exclusion Criteria 
 
1. Known pregnancy, either on household questionnaire or clinic visit.  
2. Any case with self-reported history of diabetes in household questionnaire. 
3. According to the Canadian Diabetic Association, to diagnose diabetes, anyone with the 
fasting blood glucose greater than 7 mmol/L and HbA1c% greater than 6.5% and who do 
not have any symptoms of hyperglycemia, needs confirmatory test to diagnose diabetes. 
As we do not have any information on the symptoms or on confirmatory test, anyone 
with fasting blood glucose of greater than 7mmol/L and HbA1c% greater than and equal 
to 6.5% were excluded. 
4. Chronic conditions were excluded, as CRP could be high in those conditions. This 
includes self-reported history of: asthma, rheumatoid arthritis, chronic bronchitis, 
emphysema, chronic obstructive pulmonary disease, heart disease, heart attack, history of 
stroke, kidney dysfunction or disease or on dialysis, organ transplant, or liver or gall 
bladder problems. 
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5. Anyone who received chemotherapy in the previous four weeks. 
6. Anyone with an acute condition (cold, flue, trauma, acute infection) was also excluded as 
these conditions can also cause elevated CRP. 
7. Certain medications can alter the response of the inflammatory markers. To account this 
effect people taking platelet aggregation inhibitors and HMG-CoA reductase inhibitors 
were excluded.  
 
4.6 Dependent Variable 
 
Dependent variable (HOMAIR) is a continuous variable. Insulin Resistance (HOMAIR) is 
calculated by: 
Fasting Glucose (mmol/L) x Fasting Insulin (uUnits/L) / 22.5 
 
4.7 Independent Variables 
 
High Sensitive CRP (hs-CRP) was originally a continuous variable. Population studies have 
shown that people with hs-CRP greater than 3 mg/L are at highest risk of cardiovascular 
complications126. As such, for this study we categorized hs-CRP into two categories with the cut-
off of 3mg/L.  
 
Sex is used as the dichotomous variable, male and female. Standing height, waist and hip 
circumference, high density lipoproteins, low density lipoprotein, serum triglycerides, and 
systolic and diastolic blood pressure were taken continuous variables.  
 
BMI was used a categorical variable with six categories, using the CHMS classification:  
1. = < 18.5 
2. = 18.5-24.99 
3. = 25-29.99 
4. = 35-34.99 
5. = 35-39.99 
6. = 40 and above 
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Respondents were asked to identify their cultural and racial origin. The categories of race were 
aggregated into six categories to allow for comparison with adequate numbers in each group 
which are as follows:  
1. Whites 
2. Korean, Chinese, Japanese, Filipino,  
3. South East Asians, South Asians, Western Asians 
4. Black 
5. Aboriginal (North American Indian, Metis, or Inuit) 
6. Others (Latin, Multiple origins, Arab, and others) 
 
To maintain the confidentiality of the survey participants, the minimum number of subjects in a 
cell cannot be less than thirty.  Later, for the analysis, to ensure the adequate number of subjects 
for each cell, race was further aggregated into three categories and are as follows: 
1. Whites 
2. Korean, Chinese, Japanese, Filipino, South East Asians, South Asians and Western 
Asians  
3. Black, Aboriginal, Others, Latin American, Arabs and others  
 
Age was initially a continuous variable in the survey, but based on description, it was divided 
into four categories. Respondents were categorized into: 
1. = Age 18 and 31years 
2. = Age 31 and 46 years 
3. = Age 46 and 60 years 
4. = Age 60 years and above 
 
In the CHMS study, smoking was categorized as self-reported type of smoker (daily, occasional, 
former daily, former occasional and never smoked). We grouped the smoking status categories 
into three categories as follows: 
1. = Current Smoker 
2. = Former Smoker 
3. = Never Smoker 
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Patients in the non-diabetic category were divided into three categories. Data was divided so one 
subject was counted in each category. The categories are as follows: 
1. HbA1c % less than 5.6% and Fasting Glucose less than 5.5mmol/L 
2. HbA1c% 5.6-6% or Fasting Glucose between 5.5 and 6.1mmol/L 
3. HbA1c greater than 6% or less than 6.5% or Fasting Glucose greater than 6.1 mmol/L 
and less than mmol/L  
 
Each independent variable was put into the model individually to determine its relationship with 
the outcome variable. Only the variables reaching the initial cut-off significance of p £ 0.25 were 
placed in the multiple linear regression model. Once a model with only significant predictors was 
established, the variables were tested for possible interactions and confounding. 
 
4.8 Methods 
 
CHMS cycles one, two, and three were used for this study. The data in each cycle was cleaned 
separately to select the variable of interest. All data files from the three cycles were merged with 
the combined weight file as per the Statistics Canada Guidelines.  
 
The total number of participants in CHMS cycle one, two,  and three was 17,695. After selecting 
participants from the fasted subsample who were eighteen years and older and did not have any 
history of self-reported diabetes, and if HbA1c and fasting blood glucose was less than 6.5% and 
7mmol/L respectively, we have a total sample size of 4828. 837 who have been identified with a 
chronic disease and 326 respondents with an acute condition were also excluded. 266 
respondents were excluded who were taking either antiplatelet or HMG Co-reductase inhibitors. 
There was some missing data related to CRP, LDL, and HDL and those cases were removed 
from the study. 2963 cases were included in the final analysis. (Appendix D). 
 
4.9 Statistical Analysis 
 
CHMS is a complex survey design. All variables with statistical significance of p<0.20 in 
bivariable analysis were included in the multivariable analysis. The two-sample student t-test 
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was conducted to compare the means between groups127,128. One-way ANOVA was used to 
compare means of three or more groups127,128. 
 
To determine the quality of an estimate using the coefficient of variation (CV) or to calculate 
confidence intervals, the standard error of the estimate was calculated. The standard error is the 
square root of the sampling varianc129. Since the CHMS uses a multi-stage survey design, there 
is no simple formula that can be used to calculate sampling variance. Instead, the bootstrap re-
sampling method is used to consider the sample design information and to easily obtain variance 
estimates. This method selects in each stratum, a simple random sample of (n-1) of the n first 
stage sampling units selected with replacement to form a replicate. In each replicate, the survey 
weight for each record in the (n-1) selected first stage sampling units is recalculated. These 
weights are then post-stratified according to demographic information in the same way as the 
survey weights to obtain the final bootstrap weights. This process is repeated 500 times for the 
CHMS. Combined bootstrap weights for C1, C2 and C3 provided by Statistics Canada were used 
for variance and sample weights for point estimation were applied129.  
 
As HOMAIR was not normally distributed, log transformation was done to satisfy the 
assumption of multiple linear regression. Bivariable linear regression was conducted using log 
HOMAIR as a dependent variable and including each independent variable at a time in simple 
regression model. All independent variables had p < 0.2 except smoking and age category 2 (31-
45 years). As smoking can cause high CRP, it was kept in the multivariable model because of its 
biological significance. (Appendix E). 
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CHAPTER FIVE: RESULTS 
______________________________________________________________________________ 
 
 
5.1 Population Characteristics 
 
The overall response rate of people who fasted was equivalent for both male and female 
participants (male = 46.5% and female 46.5%). In the final analysis, there was a total of 2963 
participants that represented 7,234,480 members of the Canadian population. There were 1426 
males and 1537 females. Cases in age category 1 (18-30 years), category 2 (31-45 years), 
category 3 (46-60 years), and category 4 (61 and older) were 667, 1031, 714 and 551 
respectively. 2293 cases were present in the hs-CRP category that were less than and equal to 
3mg/L, and 670 cases were present in hs-CRP category greater than 3mg/L. In the smoking 
category, 574 cases were current smokers, 813 former smokers, and 1576 never smokers. The 
population was predominately of White ethnicity (n=2373) followed by Korean, Japanese, 
Filipino (n=189), South East, South and West Asian (n=142), Black (n=83), and Aboriginal 
(n=56). There were 1799 cases if HbA1c % <5.6% and fasting glucose <5.5mmol/L; 947 cases if 
HbA1c% in the range 5.6-6% and fasting glucose between 5.5 and 6.1mmol/L; and 217 cases if 
HbA1c > 6% and <6.5% or fasting glucose >6.1 mmol/L and <mmol/L (Table 5.1). Mean 
adjusted HOMAIR was calculated using one-way ANOVA. Mean unadjusted HOMAIR in males 
was 2.30((±1.81) (mean(( ± S.E.)) and in females was 1.93((±1.49). Mean unadjusted HOMAIR 
was 2.30((±1.66), 2.05((±1.63), 2.14((±1.67), 2.26((±1.68) for age groups 18-30 years, 31-45 
years, 46-60 years and older than 61 years respectively. Mean unadjusted HOMAIR was 1.86(( ± 
1.37) and 2.94 ±(( 2.21) for CRP < 3 and CRP > 3 respectively. For non-diabetics, unadjusted 
HOMAIR was 1.86((±1.43), 2.29((±1.65), 3.34((±2.55) if HbA1c < 5.6% and FBG < 
5.5mmol/L, HbA1c 5.6-5.9% or FBG 5.5-6 mmol/L, and HbA1c 6-6.4% or FBG 6.1-6.9mmol/L 
respectively.  In the current-smoker category, it was 2.01((±1.53), in the former-smoker 
2.23((±1.83), and in the never-smoker 2.08((±1.66). The mean unadjusted HOMAIR was 
2.08((±1.64) among study participants of White ethnicity; 1.76 ((±1.15) in Korean, Japanese, and 
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Filipino; 2.45((±1.94) in South East, South and West Asian; 2.54 ((±1.88) in Black; 2.65((±2.03) 
in Aboriginal; and 2.33((±1.77) in Others. (Table 5.1) 
 
 
Table 5. 1 Population Characteristics 
 Unadjusted HOMAIR 
Mean((±SD)  
Sex  
Male (n=1426) 2.30((±1.81) 
Female (n=1537) 1.93((±1.49) 
Age  
18-30 (n=667) 2.30((±1.66) 
31-45 (n=1031) 2.05((±1.63) 
46-60 (n=714) 2.14((±1.67) 
Older than 61 (n=551) 2.26((±1.68) 
C Reactive Protein  
Less than 3mg/L(n=2293)  1.86((±1.37)  
More than 3mg/L (n=670) 2.94((±2.21)  
Smoking Category  
Current Smoker (n=574) 2.01((±1.53) 
Former Smoker (n=813) 2.23((±1.83) 
Never Smoker (n=1576) 2.08((±1.66) 
Race  
White (n=2372) 2.08((±1.64) 
Korean, Japanese, Filipino (n=189) 1.76((±1.15) 
South East, South and West Asian 
(n=142) 
2.45((±1.94) 
Black (n=83) 2.54((±1.88) 
Aboriginal (n=56) 2.65((±2.03) 
Others (n=120) 2.33((±1.77) 
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Non-Diabetic Category  
HbA1c < 5.6 and FBG < 5.5 (n=1799) 1.86((±1.43)  
HbA1c 5.6-5.9 or FBG 5.5-6 (n=947) 2.29((±1.65) 
HbA1c 6-6.4 or FBG 6.1-6.9 (n=217) 3.34((±2.55) 
 
5.2 Mean of Independent Variable in the Total Population by Sex 
 
 
Mean ((± S.E.) age at the time of clinic visits was 42.79((±15) years for males and 43((±15) 
years for females. Mean insulin (pmol/L) ((±S.E) was 65.5((±47.81), 70.17((±52.01), 
61.46((±43.1) in the total population, males and females respectively. Mean insulin (used in the 
calculation of HOMAIR) was lower in females than males, which was consistent with the 
evidence that females have lower insulin resistance. Mean glucose (mmol/L) was 4.93((± 0.49), 
5.05((±0.48), and 4.82((±0.49) in the total population, males and females respectively. Mean 
CRP (mg/L) was 2.18((±2.49) in the total population, 1.91((±2.19) in males, and 2.44((±2.70) in 
females. Mean CRP was slightly higher in females than males. In the multivariate model, CRP 
was used as a categorical variable with the cut-off of 3 mg/L and, therefore, would not affect the 
results. Mean HDL (mmol/L) was 1.41((± 0.39) in the total population, 1.25((±0.31) in males, 
and 1.54((±0.41) in females.  Mean triglycerides (mmol/L) in the total population was 1.29((± 
0.77), in males was 1.42((±0.89) and in females was 1.18((±0.62). Mean LDL (mmol/L) was 
3.04((± 0.99), 3.19((±1.04), and 2.90((±0.92) in the total population, male, and female 
respectively. Mean BMI was 26.63 in the total population, 27((±4.59) in males and 26((±5.55) in 
females (Table 5.2). 
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Table 5. 2 Mean and Standard Deviation of Independent Variables in Male And Female 
  Mean((±SD)     Mean((±SD) 
Male 
   Mean((±SD) 
     Female 
p- value 
Insulin 65.5((±47.81) 70.17((±52.01) 61.46((±43.1) <0.0001 
Glucose  4.93((±0.49) 5.05((±0.48) 4.82((±0.49) <0.0001 
C-reactive protein  2.18((±2.49) 1.91((±2.19) 2.44((±2.70) <0.0001 
HOMAIR 2.10((±1.66) 2.30((±1.81) 1.92((±1.47) <0.0001 
HDL cholesterol  1.41((±0.39) 1.25((±0.31) 1.54((±0.41) <0.0001 
Triglycerides  1.29((±0.77) 1.42((±0.89) 1.18((±0.62) <0.0001 
LDL cholesterol  3.04((±0.99) 3.19((±1.04) 2.90((±0.92) <0.0001 
Total cholesterol 4.99((±1.004) 5.0((±1.01) 4.97((±0.99) <0.0001 
Hip Circumference  35.84((±5.93) 40.55((±3.32) 40.74((±4.71) <0.0001 
Waist Circumference  40.65((±4.10) 37.59((±5.32) 34.21((±6.01) <0.0001 
Body Mass Index  26((±5) 27((±4.59) 26((±5.55) <0.0001 
Average Systolic BP 110((±14) 112.18((±13) 108.15((±16) <0.0001 
Average Diastolic BP 70((±9) 73((±9) 68((±8) <0.0001 
Age at clinic visit 43((±15) 42.79((±15) 43((±15) <0.0001 
 
(Value of Insulin in pmol/L, Glucose in mmol/L, CRP in mg/L, HDL, Triglycerides, LDL, Total 
Cholesterol in mmol/L, Hip and Waist Circumference in inches, Blood pressure in mmHg) 
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5.3 Mean of Independent Variable in the Total Population by Race 
 
Study participants of White ethnicity were slightly older [Mean ((±S.E.): 44((±15)] compared to 
Korean, Japanese, Filipinos, East, South and West Asian 39((±13) and Aboriginal, Black and 
Others 39((±14). Fasting insulin levels were the highest in Aboriginal, Black and Others 
77.93(±54.79), followed by Whites 64.49((±47.05) and Korean, Japanese, Filipinos, East, South 
and West Asian 64.38((±46.12). Fasting glucose values were very close in all three categories of 
Race 4.95((±0.50), 4.90((±0.46), 4.87((±.48). Body mass index was highest in Aboriginal, Black 
and Others 27.36((±5.77), followed by Whites 26.84((±5.14) and Korean, Japanese, Filipinos, 
East, South and West Asian 24.59((±4.09). Waist circumference was highest in Aboriginal, 
Black and Others 36.57± ((8.13) and Whites 36.09((±5.75) followed by Korean, Japanese, 
Filipinos, East, South and West Asian 33.47((±4.46) (Table 5.3). 
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Table 5. 3: Mean and Standard Deviation of Independent Variables by RACE 
 
 Mean((± SD) Mean((±SD) 
White 
   Mean((±SD) 
Korean, Japanese, 
Filipinos, East, South 
and West Asian 
Mean((±SD) 
Aboriginal,  
Black 
And Others 
Insulin  65.5((±47.81) 64.49((±47.05) 
 
64.38((±46.12) 77.93((±54.79) 
 
 
Glucose  4.93((±0.49) 4.95((±0.50) 
 
4.90((±0.46) 
 
 
4.87((±.48) 
 
 
C-reactive protein 2.18((±2.49) 2.23((±2.51) 
 
1.78((±2.13) 
 
2.31±((2.65) 
 
 
HDL cholesterol  1.41((±0.39) 1.42((±0.41) 
 
1.34((±0.34) 
 
1.36±((0.37) 
 
 
Triglycerides  1.29((±0.77) 1.29((±0.75) 
 
1.37((±0.77) 
 
 
1.29((±0.95) 
 
 
LDL cholesterol  3.04((±0.99) 3.06((0.98) 
 
2.93((±1.02) 
 
2.99((±1.022) 
 
 
Total cholesterol  4.99((±1.004) 5.02((±1.01) 
 
4.85((±0.97) 
 
 
4.89((±0.98) 
 
 
Waist 
Circumference 
40.65((±4.10) 36.09((±5.75) 
 
33.47((±4.46) 
 
 
36.57((±8.13) 
 
 
Hip Circumference 35.84((±5.93) 36.09((±3.9) 38.53((±3.29) 
 
 
41.35((±5.69) 
 
 
Body Mass Index  26.63((±5.14) 26.84((±5.14) 
 
24.59((±4.09) 
 
 
27.36((±5.77) 
 
 
Systolic BP 110((±14) 110((±15) 
 
107((±13) 
 
108((±14) 
 
Diastolic BP 70((±9) 70((±9) 
 
70((±9) 
 
 
70((±10) 
 
 
Age at clinic visit 43((±15) 44((±15) 39((±13) 39((±14) 
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(Value of Insulin in pmol/L, Glucose in mmol/L, CRP in mg/L, HDL, Triglycerides, LDL, Total 
Cholesterol in mmol/L, Hip and Waist Circumference in inches, Blood pressure in mmHg) 
 
 
 
Table 5. 4: Mean and Standard Deviation of Independent by Various Levels of Glucose 
and HbA1c 
  
  Mean ((±SD) Mean((±SD) 
HbA1c < 5.6 
and FBG < 
5.5 
Mean((±SD) 
HbA1c 5.6-5.9 
or FBG 5.5-6 
Mean((±SD) 
HbA1c 6-6.4 or 
FBG 6.1-6.9 
Insulin  65.5((±47.81) 60.7((±45.2) 69.22((±46.39) 91.10((±63.10) 
Glucose  4.93((± 0.49) 4.76((±0.34) 5.09((±0.49) 5.62((±0.68) 
C-reactive protein  2.18 ((± 2.49) 1.99((±2.36) 2.38((±2.62) 2.91((±2.69) 
HDL cholesterol  1.41((± 0.39) 1.42((±0.39) 1.4((±0.40) 1.32((±0.36) 
Triglycerides  1.29((± 0.77) 1.20((±0.67) 1.38((±0.83) 1.68((±1.07) 
LDL cholesterol  3.04((± 0.99) 4.83((±0.96) 3.23((±1.02) 3.36((±1.14) 
Total cholesterol  4.99((± 1.004) 4.84((±0.96) 5.20((±1.02) 5.32((±1.08) 
Waist 
Circumference  
35.84((± 5.93) 35.08((±5.88) 36.74((±5.75) 38.21((±5.97) 
Hip 
Circumference 
40.65((±4.10) 40.33((±4.04) 41.034((±4.08) 41.69((±4.37) 
Body Mass Index  26.63((± 5.14) 26.02((±4.93) 27.34((±5.24) 28((±5.55) 
Systolic BP 110.1((±14.88) 107((±13.38) 113((±16.29) 117((±15.49) 
Diastolic BP 70.72((± 9.31) 69.57((±9.02) 72.18((±9.53) 73.92((±9.00) 
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5.4 Observed (Unadjusted) HOMAIR 
 
When we analyzed the threshold of HOMAIR between male and females, the cut-off of 
Observed HOMAIR was 2.88 for males and 2.33 for females at the 75th percentile. (Table 5.5.1). 
 
 
 
 
Table 5.5: Percentile of Observed HOMAIR in Male and Female 
 
Observed HOMAIR in Males:           Mean 2.30((±1.81)              75th Percentile at 2.88 
Observed HOMAIR in Females:       Mean 1.93((±1.47)              75th Percentile at 2.35 
          
   
Males 
 
Females 
N   
N= 1426 
 
N = 1537 
Percentiles 10 .7999 .7066 
 20 1.0174 .9294 
 25 1.1340 1.0000 
 30 1.2560 1.0889 
 40 1.5110 1.2910 
 50 1.7825 1.5048 
 60 2.0978 1.7733 
 70 2.5689 2.1255 
 75 2.8819 2.3497 
 80 3.3023 2.6514 
 90 4.4202 3.5540 
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The association of insulin resistance (HOMAIR) with C-reactive protein was significant after 
controlling for sex, HDL, triglyceride, blood pressure, waist and hip circumference, BMI, race, 
and age.  As association was significant for Sex and CRP. Predicted values for logHOMAIR was 
calculated and the predicted mean (adjusted HOMAIR mean) was reported after taking the 
antilog. 
 
5.5 Association between Adjusted HOMAIR and CRP by Age from a Multivariable Model: 
 
Adjusted insulin resistance was higher in all age categories with high CRP for the adjusted 
model for BMI and waist circumference.  HOMAIR from the adjusted model in different age 
groups was: Age category 1 (18-30 years) 1.56((±0.59) and 2.76((±2) for low and high CRP and 
was statistically significant; Age category 2 (31-45 years) was 1.60((±0.77) and 2.58((±1.28) for 
low and high CRP; Age category 3 (46-60 years) was 1.68((±0.7) and 2.66((±1.3) for low and 
high CRP, and; Age Category 4 (61 and older) was 1.82((±0.78) and 2.44((±1.09_ for low and 
high CRP (Table 5.7). 
 
 
Table 5. 6 Adjusted HOMAIR with High and Low CRP by Age (Adjusted for sex, race, 
smoking, blood pressure, systolic and diastolic blood pressure, BMI, waist circumference, 
HDL, LDL, serum total cholesterol)  
 
Adjusted 
HOMAIR 
Mean  
(95% CI) 
Age (yrs) CRP < 3mg/L  CRP>3mg/L  P-value 
18-30 1.56((±0.59) 2.76((±2.00) <0.0001 
31-45 1.60((±0.77) 2.58((±1.28) <0.0001 
46-60 1.68((±0.70) 2.66((±1.30) <0.0001 
Older than 61 1.82((±0.78) 2.44((±1.09) <0.0001 
 
44 
 
 
 
Figure 5. 1 Error Bar Plot: Association between CRP and HOMAIR by Age 
 
 
5.6 Adjusted HOMAIR with CRP by Sex 
 
Insulin resistance was higher in males than females. Adjusted HOMAIR((±SD) in males was 
1.81((± .79) and 2.88((±1.39) with low and high CRP respectively. However, in females adjusted 
HOMAIR is 1.48((±.59) and 2.43((±1.412) with low and high CRP respectively. (Table 5.7).  
When stratified by age, in men HOMAIR was 1.63((±0.61) in age category 18-30 years with low 
CRP, and 3.11((±1.71) for high CRP, 1.83((±0.89) in age category 31-45 years with low CRP 
and 2.82((±1.13) with high CRP, 1.86((±0.76) in age category 46-60 years with low CRP and 
2.95((±1.62) with high CRP and 1.99((±0.84) in age category over 61 years with low CRP and 
2.75((±1.28) with high CRP.  
 
In females, adjusted HOMAIR was: 1.49((±0.56) in age category 18-30 years with low and CRP 
2.61((±2.11) for high CRP, 1.36((±0.52) in age category 31-45 years with low CRP and 
2.39((±1.37) with high CRP, 1.48((±0.59) in age category 46-60 years with low CRP and 
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2.48((±1.01) with high CRP and 1.68((±0.69) in age category over 61 years with low CRP and 
2.26((±0.93) with high CRP (Table 5.8). 
 
 
 
 
 
 
Figure 5. 2 Error Bar Plot: Association between CRP and HOMAIR by Sex: 
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Table 5. 7: Difference in Insulin Resistance with High and Low CRP in Male and Female 
 
 
 
Adjusted 
HOMAIR 
Mean((±SD) 
  
CRP < 3mg/L 
  
CRP>3mg/L 
 
p-value 
Male 1.81((± 0.79) 
 
 
2.88((±1.39) <0.0001 
 
Female 1.48((±0.59) 
 
 
2.43((±1.412) 
 
<0.0001 
 
 
 
 
 
 
Table 5. 8: Difference in Insulin Resistance with High and Low CRP in Male and Female 
by Age 
 
 
 
Adjusted 
HOMAIR 
Mean 
((±SD) 
 
AGE 
(yrs) 
CRP < 3mg/L  CRP>3mg/L p-value 
Male Female Male Female  
18-30 1.63((±0.61) 
 
 
1.49((±0.56) 
 
 
3.11((±1.71) 
 
2.61((±2.11) 
 
<0.0001 
31-45 1.83((±0.89) 
 
 
1.36((±0.52) 
 
 
2.82((±1.130) 
 
 
2.39((±1.37) 
 
<0.0001 
46-60 1.86((±0.76) 
 
 
1.48((±0.59) 
 
 
2.95((±1.62) 
 
 
2.48((±1.01) 
 
 
<0.0001 
Older 
than 61 
1.99((±0.84) 
 
 
1.68((±0.69) 
 
2.75((±1.28) 
 
2.26((±0.93) <0.0001 
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5.7 Adjusted HOMAIR with CRP by Ethnicity  
 
Mean adjusted HOMAIR in Whites was 1.63((±0.69)(1.59-1.66) with CRP < 3 mg/L and higher 
with high CRP at 2.57((±1.44)(2.44-2.69) with CRP > 3mg/L. In Korean, Chinese, Japanese and 
Filipino, South East Asian, South and West Asian mean adjusted HOMAIR was 
1.62((±0.56)(1.55-1.68) and 2.51((±1.13)(2.22-2.81) with low and high CRP respectively. Mean 
adjusted HOMAIR in Black, Aboriginal and Others when CRP was low was 1.91((±1.08)(1.76-
2.06) and when CRP was high was 3.07((±1.36)(2.72-3.41) (Table 5.9). 
 
 
Table 5. 9: Difference in Insulin Resistance with High and Low CRP by Ethnicity 
 
 
 
 
 
 
Adjusted 
HOMAIR 
Mean ((±SD) 
  
CRP < 3mg/L 
 
CRP>3mg/L 
 
p-value 
White 1.63((±0.69) 2.57((±1.44) <0.0001 
Korean, Chinese, 
Japanese and 
Filipino, South 
East, South and 
West Asian 
1.62((±0.56) 2.51((±1.13) <0.0001 
Black, Aboriginal, 
Others (Arabs and 
Latin American) 
1.91((±1.08) 3.7((±1.36)  <0.0001 
 
 
 
5.8 Adjusted HOMAIR with CRP by Various Levels of Glucose and HbA1c 
 
 
Mean adjusted HOMAIR for HbA1c < 5.6% and FBG < 5.5 mmol/L was 1.57((±0.64) (1.54-
1.60) and 2.44((±1.37) (2.31-2.59) with low and high CRP respectively. If HbA1c was between 
5.6-5.9% and fasting blood glucose was between 5.5-6 mmol/L, mean adjusted HOMAIR was 
1.74((±0.81) (1.68-1.80) with low CRP and 2.73((± 1.51) (2.54-2.93) with high CRP. If HbA1c 
was between 6-6.4% and fasting blood glucose between 6.1-6.9 mmol/L, it was 2.01((±0.88) 
(1.86-2.15) and 3.01((±1.28) (2.71-3.30) with high and low CRP respectively. 
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Table 5. 10 Difference in Insulin Resistance with High and Low CRP by Various Levels of 
Glucose and HbA1c: (Adjusted for BMI and WC) 
 
 
 
 
Adjusted 
HOMAIR 
Mean ((±SD) 
 CRP< 3mg/L 
 
CRP>3mg/L p-value 
HbA1c < 5.6 and FBG < 5.5 
 
1.57((±0.64) 2.44((±1.37) <0.0001 
HbA1c 5.6-5.9 or FBG 5.5-6 
 
1.74((±0.81) 2.73((±1.51) <0.0001 
HbA1c 6-6.4 or FBG 6.1-6.9 
 
2.01((±0.88) 3.01((± 1.28) <0.0001 
 
 
 
5.9 Confounding Factors to Consider   
 
To be a confounder130: 
 
1. The variable must be independently associated with the outcome (i.e. be a risk factor). 
2. The variable must be also associated with the exposure under study in the source 
population. 
3. It should not lie on the causal pathway between exposure and disease. 
 
Confounding is present if the relationship between HOMAIR and CRP has meaningfully 
different (difference of > 10%) interpretations when extraneous variables are present. LDL, 
blood pressure, smoking can cause high CRP. BMI, waist circumference and hip circumference 
could be related to insulin resistance. Therefore, LDL, blood pressure, smoking, BMI, hip and 
waist circumference were checked for confounding131.  
 
The coefficient for CRP category did not change meaningfully when LDL was removed from the 
model to check for confounding.  
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The crude estimate for CRP was 0.067 (Standard error of estimate of 0.015, p<0.0001) when 
blood pressure was not included in the model, and the adjusted the CRP estimate was 0.068 
(Standard error of 0.015, p<0.0001) when blood pressure was included in the model. This 
suggests blood pressure was not a confounder. Our crude estimate when smoking was not 
included in the model was 0.670074 (Standard error of estimate of 0.015, p< 0.0001) and 
adjusted estimate when smoking was in the model was 0.068 (Standard error of estimate 0.015, 
p<0.0001), which suggested that smoking is not a confounder. 
 
Age did not appear to be a confounder when two models were fitted by including age in the 
model and by excluding it. The crude estimate for CRP when waist circumference was excluded 
from the model was 0.077 (Standard Error of estimate of 0.015 and p<0.000). The crude estimate 
for CRP when BMI was not in the model was 0.076 (Standard error of estimate 0.015 and p < 
0.000). This was 10.5% higher than the adjusted estimate. Hip circumference was not a 
confounder with a crude estimate of 0.069 (Standard error of estimate is 0.015 and p<0.00) and 
an adjusted estimate of 0.068 (Standard error of estimate 0.015, p<0.000). 
 
5.10 Accounting for Possible Interactions 
 
Interaction is present when the relationship between HOMAIR and CRP is different at different 
levels of extraneous variable (smoking, age, sex)130.  
 
As smoking has been associated with high CRP, interaction between CRP and smoking was 
checked and was not statistically significant (p-value 0.666 for former smoker and 0.932 for 
former and never smoker with current smoker as a reference). 
 
Interactions for CRP and age was not significant in our results as well (p value of 0.70, 0.44 and 
0.564 for age 31-45, 46-60 and 61 and older with 18-30 as a reference category) 
 
There was no interaction between BMI and CRP in our population. Interaction for CRP and sex 
was significant (p value of less than 0.008) and was included in the model.  
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5.11 Sub-Group Analysis 
 
 
Physical activity has been shown to be inversely related to insulin resistance. The Physical 
Activity Index in cycles one and two was classified into active, moderate, or inactive based on 
the reported energy expenditure. The Physical Activity Index follows the same criteria used to 
categorize individuals in the Ontario Health Survey (OHS) and in the Campbell’s Survey on 
Well Being132. In cycles one and two, the household questionnaire asked about the frequency and 
duration of physical activity in the last three months. However, in cycle three more detailed and 
specific questions were asked about the frequency and duration of the activity over the previous 
seven days. As the physical activity data was reported differently in C3 from C1 and C2, 
subgroup analysis was conducted by merging C1 and C2 to assess the association of level of 
physical activity and HOMAIR. The total sample size was 1949 after merging C1 and C2. There 
were 470 people in the active group, 522 in the moderate active group, and 957 in the inactive 
group. We acknowledge the obvious limitations of self-reported physical activity scores to make 
correlations with measures of insulin resistance. 
 
One-way ANOVA was conducted to compare the means among all three groups with high and 
low CRP. Mean adjusted HOMAIR was highest in the inactive group and lowest in the active 
group. However, regardless of the physical activity index, adjusted HOMAIR was higher with 
high CRP. This shows that even in people who are physically active, HOMAIR is high with high 
CRP.  
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Table 5.11 Difference in Insulin Resistance with High and Low CRP by Physical Activity 
Index 
Adjusted 
HOMAIR 
Mean((±SD) 
Physical 
Activity 
Index 
CRP < 3mg/L  CRP>3mg/L  P-value 
Inactive 1.69((±0.81) 2.64((±1.53) <0.0001 
Moderate 
Active 
1.67((±0.72) 2.47((±1.27) <0.0001 
Active 1.55((± 0.62) 2.45((±1.65) <0.0001 
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CHAPTER SIX: DISCUSSION 
______________________________________________________________________________ 
 
6.1 Insulin Resistance and Age 
 
In the literature, the effect of age on insulin resistance is controversial. Some authors believe that 
age is a powerful indicator for insulin resistance and suggested that increasing insulin resistance 
with advancing age could be attributed to an increase in body fat composition and a decrease 
physical activity133, 134. Defronzo et al. demonstrated that insulin resistance increases with age by 
using the euglycemic clamp method in eighty-four healthy volunteers133-136. On the contrary, in a 
retrospective analysis of EGIR (European Group for the study of Insulin Resistance) study, when 
the euglycemic clamp method was used to determine insulin resistance, there was no increasing 
trend with age and insulin resistance137. Boden et al. concluded that insulin resistance appears to 
be more related to body fat than to the effect of age based on the uptake of glucose using the 
gold-standard euglycemic hyperinsulinemic clamp in healthy men of any age. They determined 
that body fat percentage correlated negatively with glucose uptake regardless of age138. 
Similarly, Basu et al. measured IR and insulin secretion with both meal and intravenous glucose 
minimal models and concluded that the defect in insulin action is mainly due to the degree of 
obesity rather than age in healthy adults133. 
 
We used calculated HOMAIR instead of a euglycemic clamp to determine insulin resistance, as 
discussed in Chapter 2. HOMAIR is less invasive and has a positive correlation with euglycemic 
clamp methods. In our study, after adjusting for all covariates (age, sex, race, smoking, blood 
pressure, systolic and diastolic blood pressure, BMI, waist circumference, HDL, LDL, serum 
total cholesterol) HOMAIR did not show any trend with increasing age (Table 5.6). Defronzo et 
al. in a retrospective analysis of EGIR did not adjust for sex when reporting IR with age, 
however in our study, when sex was taken into consideration, adjusted HOMAIR showed a 
positive trend with increasing age in males but not in females (Table 5.8). The Epidemiological 
Study of Renal Insufficiency in Spain (EPRICE) also used calculated HOMAIR for IR and did 
not show any association between increasing age and HOMAIR. Moreover, the EPRICE study, 
even when sex was taken into consideration, did not show any trend with age in males but did 
show a positive trend in females of fifty years and older139. 
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We have reported mean adjusted HOMAIR stratified by age and sex when CRP was low and 
high (cut-off of 3mg/L), which deviates from the current literature. In this study, adjusted 
HOMAIR increased with age in males when CRP is low, however this trend was not seen when 
CRP was high in males (Table 5.8). In females, there was no trend observed with high or low 
CRP but HOMAIR was highest in the oldest age category (older than 61 years) when CRP was 
low. Women typically begin to experience menopausal symptoms between forty and fifty-eight 
years of age140. It has also been postulated that estrogen has a protective role for IR in females, 
which presumably would correlate with a lower calculated HOMAIR in premenopausal 
populations. This was consistent with the observation that increases in insulin resistance after 
menopause can be decreased through hormone replacement therapy141. Further to the role of 
estrogen in insulin sensitivity, when estradiol was given to the male rodents in animal studies, 
diabetes was reversed142-144.  The highest HOMAIR was in the oldest age category (older than 61 
years) when CRP was low is consistent with the literature that IR is highest in menopause139. 
However, we did not see this effect when CRP was high. It was difficult to compare these 
findings with the existing literature as, to the best of our knowledge, no study has considered the 
association of HOMAIR with CRP stratified by age and sex. 
 
We had extensive data available on acute and chronic conditions in CHMS. Subjects with acute 
or chronic conditions were excluded from the analysis. Few, but not all, studies have adjusted for 
acute and chronic medical conditions. As the prevalence of chronic diseases keeps increasing 
with age, it is important to account for chronic diseases to assess the association of insulin 
resistance with inflammation. It is also crucial to see the effect on age in different sexes. In this 
study, age influenced insulin resistance in men but not in women.  
 
 
6.2 Insulin Resistance and Sex 
 
In our study, insulin resistance was higher in males than females after excluding any acute or 
chronic conditions and adjusting for all other covariates such as age, sex, race, smoking, blood 
pressure, systolic and diastolic blood pressure, BMI, waist circumference, HDL, LDL, and serum 
total cholesterol. The effect was persistent in all age categories with high or low CRP (Table 
5.8). However, when CRP was high association was strongest in the youngest age category. In 
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age group 18-30 years in males the risk of high HOMAIR was seven-times higher with high CRP 
than with low CRP and almost three-times higher in women with high CRP than low CRP.  
 
Females have a lower baseline mean HOMAIR then males139. We found lower HOMAIR in 
females than males with both low and high CRP. The greater amounts of visceral and hepatic fat, 
along with the lack of the protective effect of estrogens, may be related to higher insulin 
resistance in men than in women145-148.  This indicates that gender hormones may have an 
influence on insulin resistance. The increase in insulin resistance with menopause suggests that 
estrogens may play a role in promoting the insulin sensitivity observed in women. Some of this 
risk is also hereditary. The risk of developing overt diabetes in much higher in women whose 
mother also is diabetic. However, for men the risk is equal if either parent is diabetic.  
 
In our study inflammation (CRP) showed significant association with IR (HOMAIR) both in 
males and females in all age categories, as described in the previous section. It is consistent with 
findings found in the Peruvian adult population and the Japanese population where Bizu et al. 
and Nakanishi et al. demonstrated that high CRP is positively associated with insulin resistance 
(as measured by HOMAIR) in both males and females149,150.  
 
 
6.3 Insulin Resistance and Ethnicity  
 
In our study, insulin resistance showed a significant association with inflammation (CRP) in all 
race categories. In most cases, Asians have statistically smaller height and weight averages with 
a higher percentage of body fat than whites. This observation was consistent in our results (Table 
5.9). In the population we studied, Asians had the lowest BMI and waist circumference.  Gao et 
al. examined the association of insulin resistance between adult Chinese, Malays, and Asian 
Indians residing in Singapore, postulating that as the incidence of type 2 diabetes was different 
between ethnic groups within Asia, insulin resistance was also different151. In that study, IR was 
measured using HOMAIR. HOMAIR was found to be highest in Asian Indians. The association 
between ethnicity and insulin resistance was mediated by BMI, BMI adjusted waist 
circumference, unidentified risk factors, and, to a small extent, C-reactive protein. These findings 
suggested that excess weight may play an important role in ethnic disparities of insulin 
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resistance.  C-reactive protein was also independently associated with insulin resistance after 
adjusting for intra-abdominal adipose tissue in whites but not in African Americans152. Unlike 
these other observation studies which reported that Asians have greater insulin resistance than 
Whites153-154, we did not see higher HOMAIR in Asians as compared to Whites (Table 5.9). Due 
to the limited sample size, Asians were not analyzed separately in sub-groups. When more cycles 
of CHMS are available in future, separate analysis can be done to examine the association 
between IR and inflammation (CRP) in different Asians subgroups.  
 
Adjusted HOMAIR was higher in Blacks, Aboriginal, Arabs, and Latin American than in Whites 
and Asians. Due to our subgroup sample size limitations, analysis was not done separately in 
Black, Aboriginal, Arab, and Latin American sub-groups. Data from the First Nation Bone 
Health Study in Canada suggested that Aboriginal women have higher insulin resistance than 
White women. However, there were only weak correlations between HOMAIR and 
inflammation markers (Tumor necrosis factor alpha, interleukin-6, and C-reactive protein) and 
the association was not significant after adjustment for body fat155.  When more cycles of CHMS 
are available, data can be combined to assess any association between IR and CRP in 
Aboriginals and Black sub-groups separately.  
 
Some studies have examined the association of inflammation and IR in different ethnicities 
individually, but to our knowledge there is no significant data available as they relate to the 
Canadian population. Our study is one of the first to consider the effects of inflammation in 
different ethnicities. A possible next step would be to include additional cycles of the CHMS 
when they become available in order to increase the sample size to better assess the association 
between IR and inflammation in each ethnicity. Certain ethnicities might have stronger 
associations between IR and inflammation and may require focused interventions to treat insulin 
resistance. 
 
 
6.4 Insulin Resistance at Various Levels of Glycaemia  
 
HOMAIR has a linear relationship with HbA1c and fasting blood glucose. In our study, we 
found a positive association between IR (HOMAIR) and inflammation (CRP) at any level of 
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glycemia (Table 5.10) after adjusting for age, sex, race, smoking, blood pressure, systolic and 
diastolic blood pressure, BMI, waist circumference, HDL, LDL, and serum total cholesterol. 
Even in subgroups that do not meet any definition of prediabetes, HOMAIR was higher with 
high CRP. It may be possible that inflammation triggers insulin resistance even before any 
change is noticed in fasting glucose and HbA1c. This means that interventions can be focused on 
this stage to prevent insulin resistance and the loss of pancreatic beta cells. Future prospective 
studies are needed to determine the incidence of CVD in diabetes in a sub-group who have 
normal fasting blood glucose and HbA1c but high CRP.  
 
 
6.5 Limitations and Strengths of the Study  
 
There are several limitations to this study. A cross-sectional design of this study did not allow us 
to definitively identify a causal relationship between insulin resistance and inflammation (CRP). 
Rather, prospective studies are needed to cleanly evaluate if high CRP is a causative factor for 
insulin resistance. Another limitation was related to our ability to assess physical activity. As 
data on physical activity in CHMS cycles one and cycle two was reported differently than cycle 
three, the model was not adjusted for physical activity. Another limitation of our study was that 
in some ethnic categories, sample size was small and separate analyses for individual ethnicities 
was not possible. In the future, when more cycles of CHMS are available, this type of analysis 
would be possible through an increased sample size. Finally, we did not adjust the multivariable 
model with alcohol consumption. Heavy alcohol consumption could have negative association 
with HOMAIR139, 156,157. In other studies, alcohol consumption was reported as grams per day or 
drinks per day. However, in our data it was reported as number of drinks per week or per month. 
Due to the discrepancy in how alcohol consumption was reported and in order to include only 
important covariates to keep the multivariable model small, we did not include alcohol 
consumption in our analysis.  
 
The major strength of this study was the use of a large population-based sample (Table 5.1). The 
CHMS is an extensive survey with comprehensive information. CHMS is the first large 
population-based study that has collected information on multiple co-morbidities and clinical 
markers such as fasting insulin and glucose blood tests. It provided extensive information on 
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acute and chronic diseases, which were excluded from our analysis to avoid confounding. Also, 
to our knowledge, no studies have reported the associated between IR (inferred from HOMAIR 
calculations) and inflammation (CRP) by age and sex in a Canadian population.  
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CHAPTER SEVEN: SUMMARY AND FUTURE DIRECTIONS 
______________________________________________________________________________ 
 
7.1 Summary 
 
Insulin resistance is one of the acknowledged contributors in the pathogenesis of DM2. The 
asymptomatic stage with high insulin resistance and the stage of mild postprandial 
hyperglycemia are significant markers for patients at risk of developing diabetes. Patients at this 
phase may benefit from lifestyle modification and pharmacological intervention to prevent the 
progression of a disease. Inflammation is emerging as one of the factors of inflammation. In this 
study, we examined the association between insulin resistance (HOMAIR) and inflammatory 
marker (CRP) using data from Canadian Health Measure Survey in a non-diabetic sample 
population of Canadians. We examined differences by gender, age, ethnicity, and at different 
levels of glucose and HbA1c. To our knowledge, this is the first population-based study to 
examine the relationship between insulin resistance and inflammation by age, gender, and 
ethnicity in Canadian non-diabetic population. We demonstrated that the association between 
insulin resistance and inflammation is positive and that further prospective studies and 
interventions are needed to show that inflammation may be a causative factor of insulin 
resistance.  
 
7.2 Future Directions 
 
More prospective studies are needed to evaluate the effect of anti-inflammatory medications in 
the prevention of diabetes in the subgroup of people even with normal glucose but with high 
CRP and insulin resistance (HOMAIR). Further studies can be done on available Canadian 
statistical information to determine if people with high CRP and high IR but normal glucose 
levels are more prone to have cardiovascular complications than people with low IR and low 
CRP. This study would help to define optimal cut off values for HOMAIR in the population with 
the limitation as described above.  
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Conceptual Framework of The Canadian Health Measure Survey: 
 
 
 
Adopted from Mark S. Tremblay, Sarah Connor Gorber, Canadian Health Measures 
Survey, Brief Overview; CANADIAN JOURNAL OF PUBLIC HEALTH: NOVEMBER – 
DECEMBER 2007  
 
 
 
 
 
 
 
 
from approximately 333 individuals for a
total of 5,000 respondents (Table II lists
the CHMS sites).
For each site, dwellings with known
household composition based on newly
collected data from the 2006 Census were
stratified by age and a random sample of
dwellings was selected in each stratum.
Each selected dwelling is then contacted
and asked to provide a list of current
household members, which is used to
select survey participants. Subsamples of
the survey’s respondents are also selected
for laboratory analyses of specific environ-
mental chemicals.
Survey operations and logistics
The logistical and operational requirements
and procedures employed to collect the phys-
ical measures and biological specimens in the
clinic component of the survey are complex.6
Mobile clinics are comprised of two 53-foot-
long trailers (administrative trailer and clinic
trailer) which are connected by an enclosed
pedestrian walkway. The clinic team consists
of a manager, health measures specialists who
administer most physical measures tests
(blood pressure, anthropometry, fitness test-
ing, spirometry), laboratory technicians or
technologists who perform the phlebotomy
and process the biospecimens for storage and
shipment to the reference laboratories, clinic
coordinators, and dentists and dental
recorders. The staff travel from site to site
staying in apartment-style accommodations
at each location for approximately 6 weeks
before relocating to the next site. Staff at
Statistics Canada’s headquarters in Ottawa
provide logistical, operational, administrative,
advisory, communications and technical sup-
port to the field staff.
Developing the laboratory component of
the CHMS involved preparing procedures
for collecting, processing, analyzing, stor-
ing and shipping blood and urine speci-
mens and setting up a mobile laboratory.
Except for the DNA samples, all biological
samples collected in the clinic are
processed (e.g., centrifuged, aliquoted)
before they are shipped to the reference
laboratories. The only biospecimen test
conducted in the mobile clinic is the com-
plete blood count. To detect chronic dis-
ease, infectious disease a d environmental
chemical exposure, the blood and urine
samples are sent to three reference labora-
tories for analysis:
• Health Canada Laboratory, Bureau of
Nutritional Sciences, Nutrition Research
Division (nutrition and chronic disease
markers)
• National Microbiology Laboratory
(infectious disease, biorepository and
DNA preparation)
• L’Institut national de santé publique du
Québec (environmental biomarkers).
Ethical, legal and social issues
The ethical, legal and social issues sur-
rounding the CHMS are arguably the
most delicate and intricate elements of the
survey. The CHMS is the first survey for
which Statistics Canada has sought the
expertise of a Research Ethics Board with
informed consent being its key focus.
Participation is voluntary and participants
can decline to answer any specific ques-
tions or participate in any specific measure.
Specific written consent is obtained for
participation in the physical measures
(including biospecimen collection); receiv-
ing lab results; measurement and reporting
of reportable diseases; storage of biospeci-
mens (except DNA); and storage of DNA.
Assent is obtained from children in addi-
tion to consent from their parent or
guardian. A detailed privacy impact assess-
ment was completed and submitted to the
Office of the Privacy Commissioner of
Canada and provincial counterparts.
A biorepository oversight committee is
being established to address issues related
to storage and access to samples and to
ensure the confidentiality and privacy of
the information obtained from the
biospecimens. This committee will provide
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Figure 1. Conceptual framework for the CHMS
Shaded circles indicate interactions among the arrows.
Examples of non-modifiable population health determinants include: age, sex, ethnicity, genotype; examples of modifiable population
health determinants include: income, education, social environment, physical environment, health care system; examples of health behav-
iours include: physical activity, nutrition, alcohol and substance abuse, smoking status, medication use, sex behaviours, stress exposures;
examples of health characteristics include functional status, immunization status, stress reactivity, body weight, cardiovascular fitness, mus-
culoskeletal fitness, metabolic fitness; examples of health outcomes include detectable disease, health care system contact, disability.
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total of 5,000 respondents (Table II lists
the CHMS sites).
For each site, dwellings with known
household composition based on newly
collected data from the 2006 Census were
stratified by age and a random sample of
dwellings was selected in each stratum.
Each selected dwelling is then contacted
and asked to provide a list of current
household members, which is used to
select survey participants. Subsamples of
the survey’s respondents are also selected
for laboratory analyses of specific environ-
mental chemicals.
Survey operations and logistics
The logistical and operational requirements
and procedures employed to collect the phys-
ical measures and biological specimens in the
clinic component of the survey are complex.6
Mobile clinics are comprised of two 53-foot-
long trailers (administrative trailer and clinic
trailer) which are connected by an enclosed
pedestrian walkway. The clinic team consists
of a manager, health measures specialists who
administer most physical measures tests
(blood pressure, anthropometry, fitness test-
ing, spirometry), laboratory technicians or
technologists who perform the phlebotomy
and process the biospecimens for storage and
shipment to the reference laboratories, clinic
coordinators, and dentists a d ental
recorders. The staff travel from site to site
staying in apartment-style accommodations
at each location for approximately 6 weeks
before relocating to the next site. Staff at
Statistics Canada’s headquarters in Ottawa
provide logistical, operational, administrative,
advisory, communications and technical sup-
port to the field staff.
Developing the laboratory component of
the CHMS involved preparing procedures
for collecting, processing, analyzing, stor-
ing and shipping blood and urine speci-
mens and setting up a mobile laboratory.
Except for the DNA samples, all biological
samples collected in the clinic are
processed (e.g., centrifuged, aliquoted)
before they are shipped to the reference
laboratories. The only biospecimen test
conducted in the mobile clinic is the com-
plete blood count. To detect chronic dis-
ease, infectious disease and environmental
chemical exposure, the blood and urine
samples are sent to three reference labora-
tories for analysis:
• Health Canada Laboratory, Bureau of
Nutritional Sciences, Nutrition Research
Division (nutrition and chronic disease
markers)
• National Microbiology Laboratory
(infectious disease, biorepository and
DNA preparation)
• L’Institut national de santé p blique du
Québec (e vironmental biomarkers).
Ethical, legal and social issues
The ethical, legal and social issues sur-
rounding the CHMS are arguably the
most delicate and intricate elements of the
survey. The CHMS is the first survey for
which Statistics Canada has sought the
expertise of a Research Ethics Board with
informed consent being its key focus.
Participation is voluntary and participants
can decline to answer any specific ques-
tions or participate in any specific measure.
Specific written consent is obtained for
participation in the physical measures
(including biospecimen collection); receiv-
ing lab results; measurement and reporting
of reportable diseases; storage of biospeci-
mens (except DNA); and storage of DNA.
Assent is obtained from children in addi-
tion to consent from their parent or
guardian. A detailed privacy impact assess-
ment was completed and submitted to the
Office of the Privacy Commissioner of
Canada and provincial counterparts.
A biorepository oversight committee is
being established to address issues related
to storage and access to samples and to
ensure the confidentiality and privacy of
the information obtained from the
biospecimens. This committee will provide
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Summary of The Cycles of Canadian Health Measure Survey: 
 
 
 
 CHMS 
 
 
   
   Cycle 1 
2007-2009 New Brunswick, Quebec, 
Ontario, Alberta and British 
Columbia. 
 
n = 5600 
(6-79) 
 
 
   Cycle 2 
2009-2011 Newfoundland and Labrador, 
Nova Scotia, Quebec, 
Ontario, Manitoba, Alberta 
and British Columbia. 
 
n= 6,395 people  
(aged 3 to 79) 
 
 
    Cycle 3 
2012-2013 Ten provinces across Canada 
 
n = 5700  
(aged 3 to 79) 
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Flow Chart Summarizing Inclusion and Exclusion Criteria: 
 
 
 
 
 
 
 
 
 
	
Cycle 1, 2 and 3
N=17,695
Cycle 1,2 and 3
n = 4828
n =  3991 
n= 3665
n= 2963
Fasted-Sub Sample
18 yr and older
Exclude if  Reported h/o DM, 
HbA1c >6.5 or FBG>7 
Exclude if history of chronic 
disease
Exclude if taking antiplatelet or 
Stain (n=266)
Exclude if history of acute 
condition
Exclude Missing Data
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Final Multivariate Model: 
 
 
 
 
  
 
 
 
 
                                                                                 
          _cons    -.5032696   .0627016    -8.03   0.000    -.6262131   -.3803262
                 
           2 2      -.051329   .0193147    -2.66   0.008    -.0892008   -.0134572
CRP_cat#CLC_SEX  
                 
       BPMDPBPD     .0015579   .0007023     2.22   0.027     .0001808     .002935
       BPMDPBPS     .0001217   .0004751     0.26   0.798    -.0008098    .0010532
                 
             6      .0344283   .0201103     1.71   0.087    -.0050034    .0738599
             5      .0257118   .0290733     0.88   0.377    -.0312943    .0827179
             4      .0674231   .0241703     2.79   0.005     .0200306    .1148156
             3      .0594761   .0188679     3.15   0.002     .0224805    .0964716
             2      .0194658   .0166327     1.17   0.242    -.0131471    .0520787
           RACE  
                 
        HWMDBMI     .0174591   .0018073     9.66   0.000     .0139154    .0210028
   HWMD15IN_Hip    -.0042397   .0021113    -2.01   0.045    -.0083795   -.0000999
 HWMD14IN_Waist     .0102082   .0013944     7.32   0.000     .0074741    .0129422
                 
             3      .0140761   .0106959     1.32   0.188    -.0068962    .0350484
             2      .0097752   .0120002     0.81   0.415    -.0137543    .0333048
         smoker  
                 
      2.CRP_cat     .0682881   .0150905     4.53   0.000      .038699    .0978771
        LAB_LDL    -.0030173   .0044527    -0.68   0.498     -.011748    .0057134
       LAB_TRIG     .0729087   .0059886    12.17   0.000     .0611665    .0846509
        LAB_HDL    -.1048868    .011922    -8.80   0.000    -.1282631   -.0815105
      2.CLC_SEX     .0487658   .0104666     4.66   0.000     .0282433    .0692883
                 
             4     -.0281488   .0151409    -1.86   0.063    -.0578366     .001539
             3     -.0610892   .0128467    -4.76   0.000    -.0862787   -.0358998
             2     -.0589348   .0111149    -5.30   0.000    -.0807286    -.037141
            Age  
                                                                                 
      logHOMAIR        Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval]
                                                                                 
       Total     233.27349  2962  .078755399           Root MSE      =  .21326
                                                       Adj R-squared =  0.4225
    Residual    133.760796  2941    .0454814           R-squared     =  0.4266
       Model    99.5126941    21  4.73869972           Prob > F      =  0.0000
                                                       F( 21,  2941) =  104.19
      Source         SS       df       MS              Number of obs =    2963
> RACE  BPMDPBPS BPMDPBPD i.CRP_cat#i.CLC_SEX
. regress logHOMAIR i.Age i.CLC_SEX LAB_HDL LAB_TRIG LAB_LDL i.CRP_cat i.smoker HWMD14IN_Waist HWMD15IN_Hip HWMDBMI i.
